PublicationsPublications
2024  2023  2022  2021  2020  2019  2018  2017  2016  2015  2014  2013  2012  2011  2010 

2024

  1. Yamayoshi S, Nagai E, Mitamura K, Hagihara M, Kobayashi R, Takahashi S, Shibata A, Uwamino Y, Hasegawa N, Iqbal A, Kamimaki I, Iwatsuki-Horimoto K, Nagamura-Inoue T, Kawaoka Y. Seroprevalence of SARS-CoV-2 N antibodies between December 2021 and March 2023 in Japan. Epidemiol Infect, in press.
  2. Whitworth IT, Knoener RA, Puray-Chavez M, Halfmann P, Romero S, Baddouh M, Scalf M, Kawaoka Y, Kutluay SB, Smith LM, Sherer NM. Defining distinct RNA-protein interactomes of SARS-CoV-2 genomic and subgenomic RNAs. J Proteome Res23(1): 149-160, 2024. doi: 10.1021/acs.jproteome.3c00506. 2024. (JAN 2024)
  3. Uraki R, Imai M, Ito M, Yamayoshi S, Kiso M, Jounai N, Miyaji K, Iwatsuki-Horimoto K, Takeshita F, Kawaoka Y. An mRNA vaccine encoding the SARS-CoV-2 receptor-binding domain protects mice from various Omicron variants. NPJ Vaccines 9(1): 4, 2024 doi: 10.1038/s41541-023-00800-0. 2024. (JAN 2024)
  4. Ishizaka A, Koga M, Mizutani T, Yamayoshi S, Iwatsuki-Horimoto K, Adachi E, Suzuki Y, Kawaoka Y, Yotsuyanagi H. Association of gut microbiota with the pathogenesis of SARS-CoV-2 Infection in people living with HIV. BMC Microbiol 24(1): 6, 2024. doi: 10.1186/s12866-023-03157-5. 2024. (JAN 2024)

2023

  1. Uraki R, Kiso M, Iwatsuki-Horimoto K, Yamayoshi S, Ito M, Chiba S, Sakai-Tagawa Y, Imai M, Kashima Y, Koga M, Fuwa N, Okumura N, Hojo M, Iwamoto N, Kato H, Nakajima H, Ohmagari N, Yotsuyanagi H, Suzuki Y, Kawaoka Y. Characterization of a SARS-CoV-2 EG.5.1 clinical isolate in vitro and in vivo. Cell Rep 42(12): 113580, 2023. doi: 10.1016/j.celrep.2023.113580. 2023. (DEC 2023)
  2. Yamayoshi S, Ito M, Iwatsuki-Horimoto K, Yasuhara A, Okuda M, Hamabata T, Murakami J, Duong C, Yamamoto T, Kuroda Y, Maeda K, Kawaoka Y. Seroprevalence of SARS-CoV-2 antibodies in dogs and cats during the early and mid-pandemic periods in Japan, 2023. One Health 17:100588. doi: 10.1016/j.onehlt.2023.100588. 2023. (DEC 2023)
  3. Maemura T, Guan L, Gu C, Eisfeld A, Biswas A, Halfmann P, Neumann G, Kawaoka Y. Characterization of highly pathogenic clade 2.3.4.4b H5N1 mink influenza viruses. EBioMedicine 97: 104827, 2023. doi: 10.1016/j.ebiom.2023.104827. (NOV 2023)
  4. Iwatsuki-Horimoto K, Ito M, Okuda-Hamabata M, Takagi H, Imai M, Kawaoka Y. Cardiomyopathy does not exacerbate the severity of pneumonia caused by a SARS-CoV-2 delta variant in the J2N-k hamster model. Viruses 15(12): 2280, 2023. doi:org/10.3390/v15122280. (NOV 2023)
  5. Hou YJ, Chiba S, Leist SR, Meganck RM, Martinez DR, Schäfer A, Catanzaro NJ, Sontake V, West A, Edwards CE, Yount B, Lee RE, Gallant SC, Zost SJ, Powers J, Adams L, Kong EF, Mattocks M, Tata A, Randell SH, Tata PR, Halfmann P, Crowe JE Jr, Kawaoka Y, Baric RS. Host range, transmissibility and antigenicity of a pangolin coronavirus. Nat Microbiol 8(10): 1820-1833, 2023. doi: 10.1038/s41564-023-01476-x. (OCT 2023)
  6. Wilks SH, Mühlemann B, Shen X, Türeli S, LeGresley EB, Netzl A, Caniza MA, Chacaltana-Huarcaya JN, Corman VM, Daniell X, Datto MB, Dawood FS, Denny TN, Drosten C, Fouchier RAM, Garcia PJ, Halfmann PJ, Jassem A, Jeworowski LM, Jones TC, Kawaoka Y, Krammer F, McDanal C, Pajon R, Simon V, Stockwell MS, Tang H, van Bakel H, Veguilla V, Webby R, Montefiori DC, Smith DJ. Mapping SARS-CoV-2 antigenic relationships and serological responses. Science 382(6666): eadj0070, 2023. doi: 10.1126/science.adj0070. (OCT 2023)
  7. Uraki R, Ito M, Kiso M, Yamayoshi S, Iwatsuki-Horimoto K, Sakai-Tagawa Y, Imai M, Koga M, Yamamoto S, Adachi E, Saito M, Tsutsumi T, Otani A, Fukushi S, Watanabe S, Suzuki T, Kikuchi T, Yotsuyanagi H, Maeda K, Kawaoka Y. Antiviral efficacy against and replicative fitness of an XBB.1.9.1 clinical isolate. iScience 26(11): 108147, 2023. doi: 10.1016/j.isci.2023.108147. (OCT 2023)
  8. Chiba S, Halfmann PJ, Iida S, Hirata Y, Sato Y, Kuroda M, Armbrust T, Spyra S, Suzuki T, Kawaoka Y. Recombinant spike protein vaccines coupled with adjuvants that have different modes of action induce protective immunity against SARS-CoV-2. Vaccine 41(41): 6025-6035, 2023. doi: 10.1016/j.vaccine.2023.08.054. (SEP 2023)
  9. Guan L, Babujee L, Browning VL, Presler R, Pattinson D, Nguyen HLK, Hoang VMP, Le MQ, van Bakel H, Neumann G, Kawaoka Y. Continued circulation of highly pathogenic H5 influenza viruses in Vietnamese live bird markets in 2018-2021. Viruses 15(7): 1596, 2023. doi: 10.3390/v15071596. (JUL 2023)
  10. Chiba S, Kong H, Neumann G, Kawaoka Y. Influenza H3 hemagglutinin vaccine with scrambled immunodominant epitopes elicits antibodies directed toward immunosubdominant head epitopes. mBio 14(4): e0062223, 2023. doi: 10.1128/mbio.00622-23. 2023. (JUL 2023)
  11. Muramoto Y, Takahashi S, Halfmann PJ, Gotoh S, Noda T, Kawaoka Y. Replicative capacity of SARS-CoV-2 omicron variants BA.5 and BQ.1.1 at elevated temperatures. Lancet Microbe 4(7): e486, 2023. doi: 10.1016/S2666-5247(23)00100-3. (JUL 2023)
  12. Halfmann PJ, Uraki R, Kuroda M, Iwatsuki-Horimoto K, Yamayoshi S, Ito M, Kawaoka Y. Transmission and re-infection of Omicron variant XBB.1.5 in hamsters. EBioMedicine 93:104677, 2023. doi: 10.1016/j.ebiom.2023.104677. 2023. (JUL 2023)
  13. Kiso M, Furusawa Y, Uraki R, Imai M, Yamayoshi S, Kawaoka Y. In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir. Nat Commun 14(1): 3952, 2023. doi: 10.1038/s41467-023-39704-x. 2023. (JUL 2023)
  14. Ishizaka A, Koga M, Mizutani T, Uraki R, Yamayoshi S, Iwatsuki-Horimoto K, Yamamoto S, Imai M, Tsutsumi T, Suzuki Y, Kawaoka Y, Yotsuyanagi H. Research article antibody induction and immune response in nasal cavity by third dose of SARS-CoV-2 mRNA vaccination. Virol J 20(1): 146, 2023. doi: 10.1186/s12985-023-02113-z. 2023. (JUL 2023)
  15. Kiso M, Yamayoshi S, Iida S, Furusawa Y, Hirata Y, Uraki R, Imai M, Suzuki T, Kawaoka Y. In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir. Nat Commun 14(1): 4231. doi: 10.1038/s41467-023-40018-1. 2023. (JUL 2023)
  16. Kiso M, Yamayoshi S, Kawaoka Y. Efficacy of favipiravir against influenza virus resistant to both baloxavir and neuraminidase inhibitors. J Antimicrob Chemother 78(7): 1649-1657, 2023. doi: 10.1093/jac/dkad145. 2023. (JUL 2023)
  17. Yamamoto S, Yamayoshi S, Ito M, Sakai-Tagawa Y, Nakachi I, Baba R, Kamimoto S, Ogura T, Hagiwara S, Kato H, Nakajima H, Uwamino Y, Yagi K, Sugaya N, Nagai H, Saito M, Adachi E, Koga M, Tsutsumi T, Duong C, Okuda M, Murakami J, Furusawa Y, Ujie M, Iwatsuki-Horimoto K, Yotsuyanagi H, Kawaoka Y. Differences among epitopes recognized by neutralizing antibodies induced by SARS-CoV-2 infection or COVID-19 vaccination. iScience 26(7): 107208, 2023. doi: 10.1016/j.isci.2023.107208. 2023. (JUN 2023)
  18. Tamura D, Kawaoka Y. Omicron proliferation in the nasal cavity may explain its high infectivity. J Infect 86(6): 584-587, 2023. doi: 10.1016/j.jinf.2023.03.006. 2023. (JUN 2023)
  19. Uraki R, Ito M, Kiso M, Yamayoshi S, Iwatsuki-Horimoto K, Sakai-Tagawa Y, Imai M, Koga M, Yamamoto S, Adachi E, Saito M, Tsutsumi T, Otani A, Kashima Y, Kikuchi T, Theiler J, Yotsuyanagi H, Suzuki Y, Korber B, Kawaoka Y. Efficacy of antivirals and mRNA vaccination against an XBF clinical isolate. Lancet Reg Health West Pac 34: 100777, 2023. doi: 10.1016/j.lanwpc.2023.100777. 2023. (MAY 2023)
  20. Furusawa Y, Kiso M, Iida S, Uraki R, Hirata Y, Imai M, Suzuki T, Yamayoshi S, Kawaoka Y. In SARS-CoV-2 delta variants, Spike-P681R and D950N promote membrane fusion, Spike-P681R enhances spike cleavage, but neither substitution affects pathogenicity in hamsters. EBioMedicine 91:104561, 2023. doi: 10.1016/j.ebiom.2023.104561. 2023. (MAY 2023)
  21. Sakai-Tagawa Y, Yamayoshi S, Halfmann PJ, Wilson N, Bobholz M, Vuyk WC, Wei W, Ries H, O'Connor DH, Friedrich TC, Sordillo EM, van Bakel H, Simon V, Kawaoka Y. Sensitivity of rapid antigen tests for Omicron subvariants of SARS-CoV-2. J Med Virol 95(5): e28788, 2023. doi: 10.1002/jmv.28788. 2023. (MAY 2023)
  22. Uraki R, Ito M, Kiso M, Yamayoshi S, Iwatsuki-Horimoto K, Sakai-Tagawa Y, Furusawa Y, Imai M, Koga M, Yamamoto S, Adachi E, Saito M, Tsutsumi T, Otani A, Kashima Y, Kikuchi T, Yotsuyanagi H, Suzuki Y, Kawaoka Y. Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1. Lancet Infect Dis 23(5): 525-526, 2023. doi: 10.1016/S1473-3099(23)00132-9. 2023. (MAY 2023)
  23. Guan L, Zhong G, Fan S, Plisch EM, Presler R, Gu C, Babujee L, Pattinson D, Le Khanh Nguyen H, Hoang VMP, Le MQ, van Bakel H, Neumann G, Kawaoka Y. Highly Pathogenic H5 Influenza Viruses Isolated between 2016 and 2017 in Vietnamese Live Bird Markets. Viruses. 15(5):1093, 2023. doi: 10.3390/v15051093. 2023. (APR 2023)
  24. Uraki R, Ito M, Kiso M, Yamayoshi S, Iwatsuki-Horimoto K, Furusawa Y, Sakai-Tagawa Y, Imai M, Koga M, Yamamoto S, Adachi E, Saito M, Tsutsumi T, Otani A, Kikuchi T, Yotsuyanagi H, Halfmann P, Pekosz A, Kawaoka Y. Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate. Lancet Inf Dis 23(4): 402-403, 2023. doi: 10.1016/S1473-3099(23)00070-1. 2023. (APR 2023)
  25. Changrob S, Halfmann PJ, Liu H, Torres JL, McGrath JJC, Ozorowski G, Li L, Wilbanks GD, Kuroda M, Maemura T, Huang M, Zheng NY, Turner HL, Erickson SA, Fu Y, Yasuhara A, Singh G, Monahan B, Mauldin J, Srivastava K, Simon V, Krammer F, Sather DN, Ward AB, Wilson IA, Kawaoka Y, Wilson PC. Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody to antigenically distinct Omicron subvariants. J Clin Invest 133(8): e166844, 2023. doi: 10.1172/JCI166844. 2023. (APR 2023)
  26. Uraki R, Iida S, Halfmann PJ, Yamayoshi S, Hirata Y, Iwatsuki-Horimoto K, Kiso M, Ito M, Furusawa Y, Ueki H, Sakai-Tagawa Y, Kuroda M, Maemura T, Kim T, Mine S, Iwamoto N, Li R, Liu Y, Larson D, Fukushi S, Watanabe S, Maeda K, Wang Z, Ohmagari N, Theiler J, Fischer W, Korber B, Imai M, Suzuki T, Kawaoka Y. Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates. Nat Commun 14(1): 1620. doi: 10.1038/s41467-023-37059-x. 2023. (MAR 2023)
  27. Furusawa Y, Yamayoshi S, Kawaoka Y. The accuracy of reverse genetics systems for SARS-CoV-2: Circular polymerase extension reaction versus bacterial artificial chromosome. Influenza Other Respir Viruses 17(3): e13109. doi: 10.1111/irv.13109. 2023. (MAR 2023)
  28. Higashi-Kuwata N, Tsuji K, Hayashi H, Bulut H, Kiso M, Imai M, Ogata-Aoki H, Ishii T, Kobayakawa T, Nakano K, Takamune N, Kishimoto N, Hattori SI, Das D, Uemura Y, Shimizu Y, Aoki M, Hasegawa K, Suzuki S, Nishiyama A, Saruwatari J, Shimizu Y, Sukenaga Y, Takamatsu Y, Tsuchiya K, Maeda K, Yoshimura K, Iida S, Ozono S, Suzuki T, Okamura T, Misumi S, Kawaoka Y, Tamamura H, Mitsuya H. Identification of SARS-CoV-2 Mpro inhibitors containing P1' 4-fluorobenzothiazole moiety highly active against SARS-CoV-2. Nat Commun 14(1): 1076. doi: 10.1038/s41467-023-36729-0. 2023. (FEB 2023)
  29. Soga T, Duong C, Pattinson D, Sakai-Tagawa Y, Tokita A, Izumida N, Nishino T, Hagiwara H, Wada N, Miyamoto Y, Kuroki H, Hayashi Y, Seki M, Kasuya N, Koga M, Adachi E, Iwatsuki-Horimoto K, Yotsuyanagi H, Yamayoshi S, Kawaoka Y. Characterization of influenza A(H1N1)pdm09 viruses isolated in the 2018-2019 and 2019-2020 influenza seasons in Japan. Viruses 15(2): 535. doi: 10.3390/v15020535. 2023. (FEB 2023)
  30. Neumann G, Kawaoka Y. The COVID-19 pandemic-a potential role for antivirals in mitigating pandemics. Viruses 15(2): 303. doi: 10.3390/v15020303. 2023. (JAN 2023)
  31. Iwatsuki-Horimoto K, Ueki H, Ito M, Nagasawa S, Hirata Y, Hashizume K, Ushiwata K, Iwase H, Makino Y, Ushiku T, Akitomi S, Imai M, Saitoh H, Kawaoka Y. SARS-CoV-2 transmission from virus-infected dead hamsters. mSphere 8(1): e0041122. doi: 10.1128/msphere.00411-22. 2023. (FEB 2023)
  32. Koga M, Iwatsuki-Horimoto K, Kikuchi T, Yamayoshi S, Kawaoka Y, Yotsuyanagi H. Previous Omicron infection may be protective against reinfection with Omicron variant BA.5 for at least five months. Clin Microbiol Infect 29(1):120-121, 2023. doi: 10.1016/j.cmi.2022.09.009. (JAN 2023)
  33. Imai M, Ito M, Kiso M, Yamayoshi S, Uraki R, Fukushi S, Watanabe S, Suzuki T, Maeda K, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Halfmann P, Kawaoka Y. Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB. N Engl J Med 388(1):89-91, 2023. doi: 10.1056/NEJMc2214302. (JAN 2023)
  34. Uraki R, Ito M, Furusawa Y, Yamayoshi S, Iwatsuki-Horimoto K, Adachi E, Saito M, Koga M, Tsutsumi T, Yamamoto S, Otani A, Kiso M, Sakai-Tagawa Y, Ueki H, Yotsuyanagi H, Imai M, Kawaoka Y. Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB. Lancet Infect Dis 23(1):30-32, 2023. doi: 10.1016/S1473-3099(22)00816-7. (JAN 2023)
  35. Chiba S, Hatta M, Pattinson D, Yasuhara A, Neumann G, Kawaoka Y. Ferret model to mimic the sequential exposure of humans to historical H3N2 influenza viruses. Vaccine 41(2):590-597, 2023. doi: 10.1016/j.vaccine.2022.12.005. (JAN 2023)
  36. Takashita E, Watanabe S, Hasegawa H, Kawaoka Y. Are twindemics occurring? Influenza Other Respir Viruses 17(1): e13090. doi: 10.1111/irv.13090. (JAN 2023)
  37. Neumann G, Kawaoka Y. Which virus will cause the next pandemic? Viruses 15(1): 199, 2023. doi: 10.3390/v15010199. (JAN 2023)
  38. Hassan AHE, El-Sayed SM, Yamamoto M, Gohda J, Matsumoto T, Shirouzu M, Inoue J-i, Kawaguchi Y, Mansour RMA, Anvari A, Farahat AA. In Silico and In vitro evaluation of some amidine derivatives as hit compounds towards development of inhibitors against coronavirus diseases. Viruses 15(5): 1171, 2023. doi: 10.3390/v15051171. (MAY 2023)
  39. Hayashi Y, Nakayama J, Yamamoto M, Maekawa M, Watanabe S, Higashiyama S, Inoue JI, Yamamoto Y, Semba K. Aberrant accumulation of NIK promotes tumor growth by dysregulating translation and post-translational modifications in breast cancer. Cancer Cell Int 23(1): 57, 2023. doi: 10.1186/s12935-023-02904-y. (APR 2023)
  40. Hayashi Y, Huang X, Tanikawa T, Tanigawa K, Yamamoto M, Gohda J, Inoue JI, Fukase K, Kabayama K. Reactive oxygen species are associated with the inhibitory effect of N-(4-hydroxyphenyl)-retinamide on the entry of the severe acute respiratory syndrome-coronavirus 2. J Biochem: mvad020. doi: 10.1093/jb/mvad020. Epub ahead of print. PMID: 36888972. (MAR 2023)
  41. Nagai K, Muto Y, Miura S, Takahashi K, Naruse Y, Hiruta R, Hashimoto Y, Uzuki M, Haga Y, Fujii R, Ueda K, Kawaguchi Y, Fujii M, Kitazume S. Brain-specific glycosylation enzyme GnT-IX maintains levels of protein tyrosine phosphatase receptor PTPRZ, thereby mediating glioma growth PTPRZ glycosylation regulates glioma growth. J Biol Chem 299: 105128、2023. (SEP 2023)
  42. Fukui A, Maruzuru Y, Ohno S, Nobe M, Iwata S, Takeshima K, Koyanagi N, Kato A, Kitazume S, Yamaguchi Y, Kawaguchi Y. Dual impacts of a glycan shield on the envelope glycoprotein B of HSV-1: evasion from human antibodies in vivo and neurovirulence. mBio 14: e00992-23, 2023. (AUG 2023)
  43. Takahashi K, Kanekiyo K, Sakuda K, Muto Y, Iguchi M, Matsuda N, Hashimoto Y, Kanai K, Ogawa H, Hirase H, Kakita A, Bizen N, Takebayashi H, Kawaguchi Y, Uzuki M, Kitazume S. Brain-specific glycosylation of protein tyrosine phosphatase receptor type Z (PTPRZ) marks a demyelination-associated astrocyte subtype. J Neurochem 166: 547-559, 2023. (AUG 2023)
  44. Duncan JKS, D Xu, Licursi M, Joyce MA, Saffran HA, Liu K, Gohda J, Tyrrell DL, Kawaguchi Y, Hirasawa K. Interferon regulatory factor 3 mediates effective antiviral responses to human coronavirus 229E and OC43 infection. Front Immunol 14: 930086, 2023. (MAY 2023)
  45. Fukui A, Maruzuru Y, Takeshima K, Koyanagi N, Kato A, Kawaguchi Y. Establishment of a system to quantify wild-type herpes simplex virus-induced cell-cell fusion reveals a role of N-glycosylation of HSV-1 envelope glycoprotein B in cell-cell fusion. Microbiol Immunol 67: 114-119, 2023. (MAR 2023)
  46. Kuchitsu Y, Mukai K, Uematsu R, Takaada Y, Shinojima A, Shindo R, Shoji T, Hamano S, Ogawa E, Sato R, Miyake K, Kato A, Kawaguchi Y, Nishitani-Isa M, Izawa K, Nishikomori R, Yasumi T, Suzuki T, Dohmae N, Uemura T, Barber G N, Arai H, Waguri S, Taguchi T. STING signalling is terminated through ESCRT-dependent microautophagy of vesicles originating from recycling endosomes. Nat Cell Biol 25: 453-466. (MAR 2023)

2022

  1. Boon ACM, Darling TL, Halfmann PJ, Franks J, Webby RJ, Barouch DH, Port JR, Munster VJ, Diamond MS, Kawaoka Y. Reduced airborne transmission of SARS-CoV-2 BA.1 Omicron virus in Syrian hamsters. PLoS Pathog 18(12): e1010970, 2022. doi: 10.1371/journal.ppat.1010970. (DEC 2022)
  2. Uraki R, Halfmann PJ, Iida S, Yamayoshi S, Furusawa Y, Kiso M, Ito M, Iwatsuki-Horimoto K, Mine S, Kuroda M, Maemura T, Sakai-Tagawa Y, Ueki H, Li R, Liu Y, Larson D, Fukushi S, Watanabe S, Maeda K, Pekosz A, Kandeil A, Webby RJ, Wang Z, Imai M, Suzuki T, Kawaoka Y. Characterization of SARS-CoV-2 Omicron BA.4 and BA.5 isolates in rodents. Nature 612(7940):540-545, 2022. doi: 10.1038/s41586-022-05482-7. (DEC 2022)
  3. Takashita E, Yamayoshi S, Halfmann P, Wilson N, Ries H, Richardson A, Bobholz M, Vuyk W, Maddox R, Baker DA, Friedrich TC, O'Connor DH, Uraki R, Ito M, Sakai-Tagawa Y, Adachi E, Saito M, Koga M, Tsutsumi T, Iwatsuki-Horimoto K, Kiso M, Yotsuyanagi H, Watanabe S, Hasegawa H, Imai M, Kawaoka Y. In vitro efficacy of antiviral agents against Omicron subvariant BA.4.6. N Engl J Med 387(22):2094-2097, 2022. doi: 10.1056/NEJMc2211845. (DEC 2022)
  4. Nagai H, Saito M, Adachi E, Sakai-Tagawa Y, Yomayoshi S, Kiso M, Kawamata T, Koga M, Kawaoka Y, Tsutsumi T, Yotsuyanagi H. Casirivimab/imdevimab for active COVID-19 pneumonia persisted for nine months in a patient with follicular lymphoma during anti-CD20 therapy. Jpn J Infect Dis 75(6): 608-611, 2023. doi: 10.7883/yoken.JJID.2022.092. (NOV 2022)
  5. Yamayoshi S, Iwatsuki-Horimoto K, Okuda M, Ujie M, Yasuhara A, Murakami J, Duong C, Hamabata T, Ito M, Chiba S, Kobayashi R, Takahashi S, Mitamura K, Hagihara M, Shibata A, Uwamino Y, Hasegawa N, Ebina T, Izumi A, Kato H, Nakajima H, Sugaya N, Seki Y, Iqbal A, Kamimaki I, Yamazaki M, Kawaoka Y, Furuse Y. Age-stratified seroprevalence of antibodies against SARS-CoV-2 in the pre- and post-vaccination era, February 2020窶溺arch 2022, Japan. Emerg Infect Dis 28(11): 2198-2205, 2022. (NOV 2022)
  6. Yasuhara A, Yamayoshi S, Kiso M, Sakai-Tagawa Y, Okuda M, Kawaoka Y. A broadly protective human monoclonal antibody targeting the sialidase activity of influenza A and B virus neuraminidases. Nat Commun 13(1): 6602, 2022. (NOV 2022)
  7. Okuda M, Sakai-Tagawa Y, Koga M, Koibuchi T, Kikuchi T, Adachi E, Lim LA, Yamamoto S, Yotsuyanagi H, Negishi K, Jubishi D, Yamayoshi S, Kawaoka Y. Immunological correlates of prevention of the onset of seasonal H3N2 influenza. J Infect Dis 226(10): 1800-1808, 2022. (NOV 2022)
  8. Takashita E, Yamayoshi S, Fukushi S, Suzuki T, Maeda K, Sakai-Tagawa Y, Ito M, Uraki R, Halfmann P, Watanabe S, Takeda M, Hasegawa H, Imai M, Kawaoka Y. Efficacy of antiviral agents against the Omicron subvariant BA.2.75. N Engl J Med 387(13):1236-1238, 2022. (SEP 2022)
  9. Uraki R, Kiso M, Imai M, Yamayoshi S, Ito M, Fujisaki S, Takashita E, Ujie M, Furusawa Y, Yasuhara A, Iwatsuki-Horimoto K, Sakai-Tagawa Y, Watanabe S, Hasegawa H, Kawaoka Y. Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters. Nat Microbiol 7(8): 1252-1258, 2022. (AUG 2022)
  10. Ueki H, Ujie M, Komori Y, Kato T, Imai M, Kawaoka Y. Effectiveness of HEPA filters at removing infectious SARS-CoV-2 from the air. mSphere 7(4): e0008622, 2022. (AUG 2022)
  11. Meng F, Yang H, Qu Z, Chen Y, Zhang Y, Zhang Y, Liu L, Zeng X, Li C, Kawaoka Y, Chen H.縲€A Eurasian avian-like H1N1 swine influenza reassortant virus became pathogenic and highly transmissible due to mutations in its PA gene. Proc Natl Acad Sci U S A 119(34): e2203919119, 2022. (AUG 2022)
  12. Takashita E, Yamayoshi S, Simon V, van Bakel H, Sordillo EM, Pekosz A, Fukushi S, Suzuki T, Maeda K, Halfmann P, Sakai-Tagawa Y, Ito M, Watanabe S, Imai M, Hasegawa H, Kawaoka Y. Efficacy of antibodies and antiviral drugs against omicron BA.2.12.1, BA.4, and BA.5 subvariants. N Engl J Med 387(5):468-470, 2022. (AUG 2022)
  13. Halfmann PJ, Kuroda M, Armbrust T, Theiler J, Balaram A, Moreno GK, Accola MA, Iwatsuki-Horimoto K, Valdez R, Stoneman E, Braun K, Yamayoshi S, Somsen E, Baczenas JJ, Mitamura K, Hagihara M, Adachi E, Koga M, McLaughlin M, Rehrauer W, Imai M, Yamamoto S, Tsutsumi T, Saito M, Friedrich TC, O'Connor SL, O'Connor DH, Gordon A, Korber B, Kawaoka Y. Characterization of the SARS-CoV-2 B.1.621 (Mu) variant. Sci Transl Med. eabm4908, 2022. (AUG 2022)
  14. Patania OM, Chiba S, Halfmann PJ, Hatta M, Maemura T, Bernard KA, Kawaoka Y, Crawford LK. Pulmonary lesions induced by SARS-CoV-2 infection in domestic cats. Vet Pathol 59(4):696-706, 2022. (JUL 2022)
  15. Uraki R, Kiso M, Iida S, Imai M, Takashita E, Kuroda M, Halfmann PJ, Loeber S, Maemura T, Yamayoshi S, Fujisaki S, Wang Z, Ito M, Ujie M, Iwatsuki-Horimoto K, Furusawa Y, Wright R, Chong Z, Ozono S, Yasuhara A, Ueki H, Sakai-Tagawa Y, Li R, Liu Y, Larson D, Koga M, Tsutsumi T, Adachi E, Saito M, Yamamoto S, Hagihara M, Mitamura K, Sato T, Hojo M, Hattori SI, Maeda K, Valdez R; IASO study team, Okuda M, Murakami J, Duong C, Godbole S, Douek DC, Maeda K, Watanabe S, Gordon A, Ohmagari N, Yotsuyanagi H, Diamond MS, Hasegawa H, Mitsuya H, Suzuki T, Kawaoka Y. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2. Nature 607(7917): 119-127, 2022. (JUL 2022)
  16. Fisher T, Gluck A, Narayanan K, Kuroda M, Nachshon A, Hsu JC, Halfmann PJ, Yahalom-Ronen Y, Tamir H, Finkel Y, Schwartz M, Weiss S, Tseng CK, Israely T, Paran N, Kawaoka Y, Makino S, Stern-Ginossar N. Parsing the role of NSP1 in SARS-CoV-2 infection. Cell Rep 39(11):110954, 2022. (JUN 2022)
  17. Fujii T, Hagihara M, Mitamura K, Nakashima S, Ohara S, Uchida T, Inoue M, Okuda M, Yasuhara A, Murakami J, Duong C, Iwatsuki-Horimoto K, Yamayoshi S, Kawaoka Y. Anti-SARS CoV-2 IgG in COVID-19 patients with hematological diseases: a single-center, retrospective study in Japan. Intern Med 61(11) :1681-1686, 2022. doi: 10.2169/internalmedicine.9209-21. (JUN 2022)
  18. Darling TL, Ying B, Whitener B, VanBlargan LA, Bricker TL, Liang CY, Joshi A, Bamunuarachchi G, Seehra K, Schmitz AJ, Halfmann PJ, Kawaoka Y, Elbashir SM, Edwards DK, Thackray LB, Diamond MS, Boon ACM. mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2. Med (N Y) 3(5): 309-324.e6, 2022. (MAY 2022)
  19. Halfmann PJ, Kuroda M, Maemura T, Chiba S, Armbrust T, Wright R, Balaram A, Florek KR, Bateman AC, Kawaoka Y. Efficacy of vaccination and previous infection against the Omicron BA.1 variant in Syrian hamsters. Cell Rep 39(3): 110688, 2022. (APR 2022)
  20. Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, Iwatsuki-Horimoto K, Halfmann P, Watanabe S, Maeda K, Imai M, Mitsuya H, Ohmagari N, Takeda M, Hasegawa H, Kawaoka Y. Efficacy of antiviral agents against the SARS-CoV-2 Omicron subvariant BA.2. N Engl J Med 386(15): 1475-1477, 2022. (APR 2022)
  21. Ueki H, Ito M, Furusawa Y, Yamayoshi S, Inoue SI, Kawaoka Y. A 265-nanometer high-power deep-UV light-emitting diode rapidly inactivates SARS-CoV-2 aerosols. mSphere 7: e0094121, 2022. (APR 2022)
  22. Murakami J, Shibata A, Neumann G, Imai M, Watanabe T, Kawaoka Y. Characterization of H9N2 Avian influenza viruses isolated from poultry products in a mouse model. Viruses 14: 728. 2022. (MAR 2022)
  23. Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, Iwatsuki-Horimoto K, Chiba S, Halfmann P, Nagai H, Saito M, Adachi E, Sullivan D, Pekosz A, Watanabe S, Maeda K, Imai M, Yotsuyanagi H, Mitsuya H, Ohmagari N, Takeda M, Hasegawa H, Kawaoka Y. Efficacy of antibodies and antivirals against a SARS-CoV-2 Omicron variant. N Engl J Med 386: 995-998, 2022. (MAR 2022)
  24. Cameroni E, Bowen JE, Rosen LE, Saliba C, Zepeda SK, Culap K, Pinto D, VanBlargan LA, De Marco A, di Iulio J, Zatta F, Kaiser H, Noack J, Farhat N, Czudnochowski N, Havenar-Daughton C, Sprouse KR, Dillen JR, Powell AE, Chen A, Maher C, Yin L, Sun D, Soriaga L, Bassi J, Silacci-Fregni C, Gustafsson C, Franko NM, Logue J, Iqbal NT, Mazzitelli I, Geffner J, Grifantini R, Chu H, Gori A, Riva A, Giannini O, Ceschi A, Ferrari P, Cippテ PE, Franzetti-Pellanda A, Garzoni C, Halfmann PJ, Kawaoka Y, Hebner C, Purcell LA, Piccoli L, Pizzuto MS, Walls AC, Diamond MS, Telenti A, Virgin HW, Lanzavecchia A, Snell G, Veesler D, Corti D. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature 602(7898): 664-670, 2022. (FEB 2022)
  25. Takamatsu Y, Imai M, Maeda K, Nakajima N, Higashi-Kuwata N, Iwatsuki-Horimoto K, Ito M, Kiso M, Maemura T, Takeda Y, Omata K, Suzuki T, Kawaoka Y, Mitsuya H. Highly neutralizing COVID-19 convalescent plasmas potently block SARS-CoV-2 replication and pneumonia in syrian hamsters. J Virol 96: e01551-21, 2022. (FEB 2022)
  26. Saito A, Irie T, Suzuki R, Maemura T, Nasser H, Uriu K, Kosugi Y, Shirakawa K, Sadamasu K, Kimura I, Ito J, Wu J, Iwatsuki-Horimoto K, Ito M, Yamayoshi S, Loeber S, Tsuda M, Wang L, Ozono S, Butlertanaka EP, Tanaka YL, Shimizu R, Shimizu K, Yoshimatsu K, Kawabata R, Sakaguchi T, Tokunaga K, Yoshida I, Asakura H, Nagashima M, Kazuma Y, Nomura R, Horisawa Y, Yoshimura K, Takaori-Kondo A, Imai M; Genotype to Phenotype Japan (G2P-Japan) Consortium, Tanaka S, Nakagawa S, Ikeda T, Fukuhara T, Kawaoka Y, Sato K. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. Nature 602: 300-306, 2022. (FEB 2022)
  27. Halfmann PJ, Kuroda M, Armbrust T, Accola M, Valdez R, Kowalski-Dobson T, Rehrauer W, Gordon A, Kawaoka Y. Long-term, infection-acquired immunity against the SARS-CoV-2 Delta variant in a hamster model. Cell Rep 38: 110394, 2022. (FEB 2022)
  28. Cameroni E, Bowen J, Rosen L, Saliba C, Zepeda S, Culap K, Pinto D, VanBlargan L, Marco A, Iulio J, Zatta F, Kaiser H, Noack J, Farhat N, Czudnochowski N, Havenar-Daughton C, Sprouse K, Dillen J, Powell A, Chen A, Maher C, Yin L, Sun D, Soriaga L, Bassi J, Silacci-Fregni C, Gustafsson C, Franko N, Logue J, Iqbal N, Mazzitelli I, Geffner J, Grifantini R, Chu H, Gori A, Riva A, Giannini O, Ceschi A, Ferrari P, Cippテ P, Franzetti-Pellanda A, Garzoni C, Halfmann P, Kawaoka Y, Hebner C, Purcell L, Piccoli L, Pizzuto M, Walls A, Diamond M, Telenti A, Virgin H, Lanzavecchia A, Snell G, Veesler D, Corti D. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature 602: 664-670, 2022. (FEB 2022)
  29. Halfmann P, Iida S, Iwatsuki-Horimoto K, Maemura T, Kiso M, Scheaffer S, Darling T, Joshi A, Loeber S, Singh G, Foster S, Ying B, Case J, Chong Z, Whitener B, Moliva J, Floyd K, Ujie M, Nakajima N, Ito M, Wright R, Uraki R, Warang P, Gagne M, Li R, Sakai-Tagawa Y, Liu Y, Larson D, Osorio J, Hernandez-Ortiz J, Henry A, Ciouderis K, Florek K, Patel M, Odle A, Wong LY, Bateman A, Wang Z, Edara VV, Chong Z, Franks J, Jeevan T, Fabrizio T, DeBeauchamp J, Kercher L, Seiler P, Gonzalez-Reiche A, Sordillo E, Chang L, Bakel H, Simon V, PSP study group, Douek D, Sullivan N, Thackray L, Ueki H, Yamayoshi S, Imai M, Perlman S, Webby R, Seder R, Suthar M, Garcia-Sastre A, Schotsaert M, Suzuki T, Boon A, Diamond M, KawaokaY. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature 603: 687-692, 2022. (JAN 2022)
  30. VanBlargan LA, Errico JM, Halfmann PJ, Zost SJ, Crowe JE Jr, Purcell LA, Kawaoka Y, Corti D, Fremont DH, Diamond MS. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat Med 19: 1-6, 2022. (JAN 2022)
  31. Ohta M, Bannai H, Kambayashi Y, Tamura N, Tsujimura K, Yamayoshi S, Kawaoka Y, Nemoto M. Growth properties and immunogenicity of a virus generated by reverse genetics for an inactivated equine influenza vaccine. Equine Vet J 54: 139-144, 2022. (JAN 2022)
  32. Ogura H, Gohda J, Lu X, Yamamoto M, Takesue Y, Son A, Doi S, Matsushita K, Isobe F, Fukuda Y, Huang TP, Ueno T, Mambo N, Murakami H, Kawaguchi Y, Inoue JI, Shirai K, Yamasaki S, Hirata JI, Ishido S. Dysfunctional Sars-CoV-2-M protein-specific cytotoxic T lymphocytes in patients recovering from severe COVID-19. Nat Commun 13(1): 7063. (DEC 2022)
  33. Yamamoto M, Gohda J, Kobayashi A, Tomita K, Hirayama Y, Koshikawa N, Seiki M, Semba K, Akiyama T, Kawaguchi Y, Inoue JI. Metalloproteinase-dependent and TMPRSS2-independnt cell surface entry pathway of SARS-CoV-2 requires the furin-cleavage site and the S2 domain of spike protein. mBio e0051922, 2022. doi: 10.1128/mbio.00519-22. (JUN 2022)
  34. Yamamoto M, Tomita K, Hirayama Y, Inoue JI, Kawaguchi Y, Gohda J. SARS-CoV-2 Omicron spike H655Y mutation is responsible for enhancement of the endosomal entry pathway and reduction of cell surface entry pathways. BioRxiv, 2022. doi: https://doi.org/10.1101/2022.03.21.485084 (MAR 2022)
  35. Takeshima K, Maruzuru Y, Koyanagi N, Kato A, Kawaguchi Y. Redundant and specific roles of A-type lamins and lamin B receptor in herpes simplex virus 1 infection. J Virol 96: e0142922. (DEC 2022)
  36. Inayoshi Y, Oguro S, Tanahashi E, Lin Z, Kawaguchi Y, Kodama T, Sasakawa C. Bacterial artificial chromosome-based reverse genetics system for cloning and manipulation of the full-length genome of infectious bronchitis virus. Curr Res Microb Sci 3: 100155, 2022. (JUL 2022)
  37. Tachida Y, Miura S, Muto Y, Takuwa H, Sahara N, Shindo A, Matsuba Y, Saito T, Taniguchi N, Kawaguchi Y, Tomimoto H, Saido T, Kitazume S. Endothelial expression of human amyloid precursor protein leads to amyloid ホイ in the blood and induces cerebral amyloid angiopathy in knock-in mice. J Biol Chem 298: 101880, 2022. (JUN 2022)
  38. Maeda F, Kato A, Takeshima K, Shibazaki M, Sato R, Shibata T, Miyake K, Kozuka-Hata H, Oyama M, Shimizu E, Imoto S, Miyano S, Adachi S, Natsume T, Takeuchi K, Maruzuru Y, Koyanagi N, Arii J, Kawaguchi Y. Role of the orphan transporter SLC35E1 in the nuclear egress of herpes simplex virus 1. J Virol 96: e00306-22, 2022. (MAY 2022)
  39. Arii J, Takeshima K, Maruzuru Y, Koyanagi N, Nakayama Y, Kato A, Mori Y, Kawaguchi Y. Role of the arginine cluster in the disordered domain of Herpes Simplex Virus 1 UL34 for the recruitment of ESCRT-III for viral primary envelopment. J Virol 96: e01704-21, 2022. (JAN 2022)

2021

  1. Kong X, Guan L, Shi J, Kong H, Zhang Y, Zeng X, Tian G, Liu L, Li C, Kawaoka Y, Deng G, Chen H. A single-amino-acid mutation at position 225 in hemagglutinin attenuates H5N6 influenza virus in mice. Emerg Microbes Infect 10: 2052-2061, 2021. (DEC 2021)
  2. Kong H, Fan S, Takada K, Imai M, Neumann G, Kawaoka Y. H3N2 influenza viruses with 12- or 16-amino acid deletions in the receptor-binding region of their hemagglutinin protein. mBio 12: e0151221, 2021. (DEC 2021)
  3. Asaka MN, Utsumi D, Kamada H, Nagata S, Nakachi Y, Yamaguchi T, Kawaoka Y, Kuba K, Yasutomi Y. Highly susceptible SARS-CoV-2 model in CAG promoter-driven hACE2 transgenic mice. JCI Insight 6(19): e152529, 2021. (OCT 2021)
  4. Maemura T, Kuroda M, Armbrust T, Yamayoshi S, Halfmann PJ, Kawaoka Y. Antibody-dependent enhancement of SARS-CoV-2 infection is mediated by the IgG receptors FcホウRIIA and FcホウRIIIA but does not contribute to aberrant cytokine production by macrophages. mBio 12, 2021. (OCT 2021)
  5. Sakai-Tagawa Y, Yamayoshi S, Halfmann P, Kawaoka Y. Comparative sensitivity of rapid antigen tests for the Delta variant (B.1.617.2) of SARS-CoV-2. Viruses 13: 2183, 2021. (OCT 2021)
  6. Imai M, Halfmann PJ, Yamayoshi S, Iwatsuki-Horimoto K, Chiba S, Watanabe T, Nakajima N, Ito M, Kuroda M, Kiso M, Maemura T, Takahashi K, Loeber S, Hatta M, Koga M, Nagai H, Yamamoto S, Saito M, Adachi E, Akasaka O, Nakamura M, Nakachi I, Ogura T, Baba R, Fujita K, Ochi J, Mitamura K, Kato H, Nakajima H, Yagi K, Hattori SI, Maeda K, Suzuki T, Miyazato Y, Valdez R, Gherasim C, Furusawa Y, Okuda M, Ujie M, Lopes TJS, Yasuhara A, Ueki H, Sakai-Tagawa Y, Eisfeld AJ, Baczenas JJ, Baker DA, O'Connor SL, O'Connor DH, Fukushi S, Fujimoto T, Kuroda Y, Gordon A, Maeda K, Ohmagari N, Sugaya N, Yotsuyanagi H, Mitsuya H, Suzuki T, Kawaoka Y. Characterization of a new SARS-CoV-2 variant that emerged in Brazil. Proc Natl Acad Sci U S A 118(27): e2106535118, 2021. (JUL 2021)
  7. Dugan HL, Stamper CT, Li L, Changrob S, Asby NW, Halfmann PJ, Zheng NY, Huang M, Shaw DG, Cobb MS, Erickson SA, Guthmiller JJ, Stovicek O, Wang J, Winkler ES, Madariaga ML, Shanmugarajah K, Jansen MO, Amanat F, Stewart I, Utset HA, Huang J, Nelson CA, Dai YN, Hall PD, Jedrzejczak RP, Joachimiak A, Krammer F, Diamond MS, Fremont DH, Kawaoka Y, Wilson PC. Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets. Immunity 54(6): 1290-1303.e7, 2021. (JUN 2021)
  8. Saito M, Itoh Y, Yasui F, Munakata T, Yamane D, Ozawa M, Ito R, Katoh T, Ishigaki H, Nakayama M, Shichinohe S, Yamaji K, Yamamoto N, Ikejiri A, Honda T, Sanada T, Sakoda Y, Kida H, Le TQM, Kawaoka Y, Ogasawara K, Tsukiyama-Kohara K, Suga H, Kohara M. Macrocyclic peptides exhibit antiviral effects against influenza virus HA and prevent pneumonia in animal models. Nat Commun 12(1): 2654, 2021. (MAY 2021)
  9. Uwamino Y, Nagata M, Aoki W, Nakagawa T, Inose R, Yokota H, Furusawa Y, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Kawaoka Y, Hasegawa N, Murata M; Keio Donner Project Members. Accuracy of rapid antigen detection test for nasopharyngeal swab specimens and saliva samples in comparison with RT-PCR and viral culture for SARS-CoV-2 detection. J Infect Chemother S1341-321X(21)00117-3, 2021. (APR 2021)
  10. Takashita E, Kawakami C, Momoki T, Saikusa M, Shimizu K, Ozawa H, Kumazaki M, Usuku S, Tanaka N, Okubo I, Morita H, Nagata S, Watanabe S, Hasegawa H, Kawaoka Y. Increased risk of rhinovirus infection in children during the coronavirus disease-19 pandemic. Influenza Other Respir Viruses 15(4): 488-494, 2021. (JUL 2021)
  11. Ravichandran S, Lee Y, Grubbs G, Coyle EM, Klenow L, Akasaka O, Koga M, Adachi E, Saito M, Nakachi I, Ogura T, Baba R, Ito M, Kiso M, Yasuhara A, Yamada S, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Imai M, Yamayoshi S, Yotsuyanagi H, Kawaoka Y, Khurana S. Longitudinal antibody repertoire in "mild" versus "severe" COVID-19 patients reveals immune markers associated with disease severity and resolution. Sci Adv 7(10): eabf2467, 2021. (MAR 2021)
  12. Yamayoshi S, Yasuhara A, Ito M, Akasaka O, Nakamura M, Nakachi I, Koga M, Mitamura K, Yagi K, Maeda K, Kato H, Nojima M, Pattinson D, Ogura T, Baba R, Fujita K, Nagai H, Yamamoto S, Saito M, Adachi E, Ochi J, Hattori SI, Suzuki T, Miyazato Y, Chiba S, Okuda M, Murakami J, Hamabata T, Iwatsuki-Horimoto K, Nakajima H, Mitsuya H, Omagari N, Sugaya N, Yotsuyanagi H, Kawaoka Y. Antibody titers against SARS-CoV-2 decline, but do not disappear for several months. EClinicalMedicine 32: 100734, 2021. (FEB 2021)
  13. Kong H, Burke DF, da Silva Lopes TJ, Takada K, Imai M, Zhong G, Hatta M, Fan S, Chiba S, Smith D, Neumann G, Kawaoka Y. Plasticity of the influenza virus H5 HA protein. mBio 12(1): e03324-20, 2021. (FEB 2021)
  14. Chiba S, Halfmann PJ, Hatta M, Maemura T, Fan S, Armbrust T, Swartley OM, Crawford LK, Kawaoka Y. Protective immunity and persistent lung sequelae in domestic cats after SARS-CoV-2 Infection. Emerg Infect Dis 27(2): 660-663, 2021. (FEB 2021)
  15. Kawashima K, Hirota-Tsukimachi M, Toma T, Koga R, Iwamaru K, Yanae M, Ahagon A, Nakamura Y, Anraku K, Tateishi H, Gohda J, Inoue JI, Otsuka M, Fujita M. Development of chimeric receptor activator of nuclear factor-kappa B with glutathione S-transferase in the extracellular domain: Artificial switch in a membrane receptor. Chem Biol Drug Des 99(4): 573-584, 2021. (DEC 2021)
  16. Takeuchi Y, Kimura N, Murayama T, Machida Y, Iejima D, Nishimura T, Terashima M, Wang Y, Li M, Sakamoto R, Yamamoto M, Itano N, Inoue Y, Ito M, Yoshida N, Inoue JI, Akashi K, Saya H, Fujita K, Kuroda M, Kitabayashi I, Voon D, Suzuki T, Tojo A, Gotoh N. The membrane-linked adaptor FRS2ホイ fashions a cytokine-rich inflammatory microenvironment that promotes breast cancer carcinogenesis. Proc Natl Acad Sci USA 118(43): e2103658118. doi: 10.1073/pnas.2103658118. (OCT 2021)
  17. Yamamoto M, Gohda J, Cell-based membrane fusion assays with viral fusion proteins for identification of entry inhibitors. Translational and Regulatory Sciences 3(3): 72-76. (DEC 2021)
  18. Deletsu SD, Kitamura H, Ishida T, Gohda J, Yamaoka S, Takeuchi H. Identification and characterization of Stathmin 1 as a host factor involved in HIV-1 latency. Biochem Biophys Res Commun 567: 106-111, 2021 (AUG 2021)
  19. Hayashi Y, Tsuchiya K, Yamamoto M, Nemoto-Sasaki Y, Tanigawa K, Hama K, Ueda Y, Tanikawa T, Gohda J, Maeda K, Inoue J, Yamashit A. N-(4-Hydroxyphenyl) retinamide suppresses SARS-CoV-2 spike protein-mediated cell-cell fusion by a dihydroceramide ホ・-desaturase 1-independent mechanism. Journal of Virology 10;95(17), 2021 (AUG 2021)
  20. Kandeel M, Yamamoto M, Park BK, Al-Taher A, Watanabe A, Gohda J, Kawaguchi Y, Oh-hashi K, Kwon HJ, Inoue JI. Discovery of new potent anti-MERS CoV fusion inhibitors. Frontiers in Pharmacology 12: 685161, 2021. (JUN 2021)
  21. Kandeel M, Yamamoto M, Tani H, Kobayashi A, Gohda J, Kawaguchi Y, Park BK, Kwon HJ, Inoue JI, Alkattan A. Discovery of new fusion inhibitor peptides against SARS-CoV-2 by targeting the spike S2 subunit. Biomolecules & Therapeutics 29(3): 282-289. (MAY 2021)
  22. Yamamoto M, Gohda J, Akiyama T, Inoue JI. TNF receptor-associated factor 6 (TRAF6) plays crucial roles in multiple biological systems through polyubiquitination-mediated NF-ホコB activation. Proc Jpn Acad Ser B Phys Biol Sci 97(4): 145-160. (APR 2021)
  23. Hayashi Y, Suzuki H, Nakajima W, Uehara I, Tanimura A, Himeda T, Koike S, Katsuno T, Kitajiri S, Koyanagi N, Kawaguchi Y, Onomoto K, Kato H, Yoneyama M, Fujita T, Tanaka N. Virus-infection in cochlear supporting cells induces audiosensory receptor hair cell death by TRAIL-induced necroptosis. PLoS One 16: e0260443. (NOV 2021)
  24. Adachi A, Honda T, Dainichi T, Egawa G, Yamamoto Y, Nomura T, Nakajima S, Otsuka A, Maekawa M, Mano N, Koyanagi N, Kawaguchi Y, Ohteki T, Nagasawa T, Ikuta K, Kitoh A, Kabashima K. Prolonged high-intensity exercise induces fluctuating immune responses to herpes simplex virus infection via glucocorticoids. J Allergy Clin Immunol 148: 1575-1588. (DEC 2021)
  25. Maruzuru Y, Koyanagi N, Kato A, Kawaguchi Y. Role of the DNA binding activity of herpes simplex virus 1 VP22 in evading AIM2-dependent inflammasome activation induced by the virus. J Virol 95: e02172-20. (MAR 2021)
  26. Watanabe M, Arii J, Takeshima K, Fukui A, Shimojima M, Kozuka-Hata H, Oyama M, Minamitani T, Yasui T, Kubota Y, Takekawa M, Kosugi I, Maruzuru Y, Koyanagi N, Kato A, Mori Y, Kawaguchi Y. Prohibitin-1 contributes to the cell-to-cell transmission of herpes simplex virus 1 via the MAPK/ERK signaling pathway. J Virol 95: e01413-20. (JAN 2021)

2020

  1. Yamayoshi S, Sakai-Tagawa Y, Koga M, Akasaka O, Nakachi I, Koh H, Maeda K, Adachi E, Saito M, Nagai H, Ikeuchi K, Ogura T, Baba R, Fujita K, Fukui T, Ito F, Hattori SI, Yamamoto K, Nakamoto T, Furusawa Y, Yasuhara A, Ujie M, Yamada S, Ito M, Mitsuya H, Omagari N, Yotsuyanagi H, Iwatsuki-Horimoto K, Imai M, Kawaoka Y. Comparison of rapid antigen tests for COVID-19. Viruses 12(12): 1420, 2020. (DEC 2020)
  2. Hou YJ, Chiba S, Halfmann P, Ehre C, Kuroda M, Dinnon KH 3rd, Leist SR, Schëfer A, Nakajima N, Takahashi K, Lee RE, Mascenik TM, Graham R, Edwards CE, Tse LV, Okuda K, Markmann AJ, Bartelt L, de Silva A, Margolis DM, Boucher RC, Randell SH, Suzuki T, Gralinski LE, Kawaoka Y, Baric RS. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science 370(6523):1464-1468, 2020. (DEC 2020)
  3. Ueki H, Furusawa Y, Iwatsuki-Horimoto K, Imai M, Kabata H, Nishimura H, Kawaoka Y. Effectiveness of face masks in preventing airborne transmission of SARS-CoV-2. mSphere 5:e00637-20, 2020. (OCT 2020)
  4. Fukuyama S, Iwatsuki-Horimoto K, Kiso M, Nakajima N, Gregg RW, Katsura H, Tomita Y, Maemura T, da Silva Lopes TJ, Watanabe T, Shoemaker JE, Hasegawa H, Yamayoshi S, Kawaoka Y. Pathogenesis of influenza A(H7N9) virus in aged nonhuman primates. J Infect Dis 222(7): 1155-1164, 2020. (OCT 2020)
  5. Imai M, Iwatsuki-Horimoto K, Hatta M, Loeber S, Halfmann PJ, Nakajima N, Watanabe T, Ujie M, Takahashi K, Ito M, Yamada S, Fan S, Chiba S, Kuroda M, Guan L, Takada K, Armbrust T, Balogh A, Furusawa Y, Okuda M, Ueki H, Yasuhara A, Sakai-Tagawa Y, Lopes TJS, Kiso M, Yamayoshi S, Kinoshita N, Ohmagari N, Hattori SI, Takeda M, Mitsuya H, Krammer F, Suzuki T, Kawaoka Y. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc Natl Acad Sci USA 117(28): 16587-16595, 2020. (JUL 2020)
  6. Yamamoto M, Kiso M, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Imai M, Takeda M, Kinoshita N, Ohmagari N, Gohda J, Semba K, Matsuda Z, Kawaguchi Y, Kawaoka Y, Inoue JI. The anticoagulant nafamostat potently inhibits SARS-CoV-2 S protein-mediated fusion in a cell fusion assay system and viral infection in vitro in a cell-type-dependent manner. Viruses 12(6): 629, 2020. (JUN 2020)
  7. Kiso M, Yamayoshi S, Kawaoka Y. Triple combination therapy of favipiravir plus two monoclonal antibodies eradicates influenza virus from nude mice. Commun Biol 3(1): 219, 2020. (MAY 2020)
  8. Feng H, Nakatsu S, Lopes TJDS, Imai M, Yamayoshi S, Yamashita M, Watanabe T, Kawaoka Y. Identification of novel adjuvants for ebola virus-like particle vaccine. Vaccines (Basel) 8: E215, 2020. (MAY 2020)
  9. Kato-Miyashita, S, Sakai-Tagawa Y, Yamashita M, Iwatsuki-Horimoto K, Ito M, Tokita A, Hagiwara H, Izumida N, Nishino T, Wada N, Koga M, Adachi E, Jubishi D, Yotsuyanagi H, Kawaoka Y, Imai M. Antigenic variants of influenza B viruses isolated in Japan during the 2017窶・018 and 2018窶・019 influenza seasons. Influenza Other Respi Viruses 14: 311-319, 2020. (MAY 2020)
  10. Kiso M, Yamayoshi S, Murakami J, Kawaoka Y. Baloxavir marboxil treatment of nude mice infected with influenza A virus. J Infect Dis 221: 1699-1702, 2020. (APR 2020)
  11. Ueki H, Wang IH, Zhao D, Gunzer M, Kawaoka Y. Multicolor two-photon imaging of in vivo cellular pathophysiology upon influenza virus infection using the two-photon IMPRESS. Nat Protoc 15: 1041-1065, 2020. (MAR 2020)
  12. Wu L, Mitake H, Kiso M, Ito M, Iwatsuki-Horimoto K, Yamayoshi S, Lopes TJS, Feng H, Sumiyoshi R, Shibata A, Osaka H, Imai M, Watanabe T, Kawaoka Y. Characterization of H7N9 avian influenza viruses isolated from duck meat products. Transboundary and Emerging Diseases 67: 792-798, 2020. (MAR 2020)
  13. Maemura T, Fukuyama S, Kawaoka Y. High levels of miR-483-3p are present in serum exosomes upon infection of mice with highly pathogenic avian influenza virus. Front Microbiol 11: 144, 2020. (FEB 2020)
  14. Zhong G, Fan S, Hatta M, Nakatsu S, Walters KB, Lopes TJS, Wang JI, Ozawa M, Karasin A, Li Y, Tong S, Donis RO, Neumann G, Kawaoka Y. Mutations in the NA-like protein of bat influenza H18N11 virus enhance virus replication in mammalian cells, mice, and ferrets. J Virol 94: e01416-19, 2020. (FEB 2020)
  15. Mitake H, Yasuhara A, Lopes TJS, Tagawa-Sakai Y, Shimizu K, Ozawa H, Kawakami C, Morikawa S, Sugaya N, Watanabe T, Kawaoka Y. Comparison of the Pathogenicity in Mice of A(H1N1)pdm09 Viruses Isolated between 2009 and 2015 in Japan. Viruses 12(2). pii: E155, 2020. (JAN 2020)
  16. Imai M, Yamashita M, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Kiso M, Murakami J, Yasuhara A, Takada K, Ito M, Nakajima N, Takahashi K, Lopes TJS, Tokita A, Hagiwara H, Izumida N, Kuroki H, Nishino T, Wada N, Koga M, Adachi E, Jubishi D, Hasegawa H, Kawaoka Y. Influenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are fit and transmit through respiratory droplets. Nature Microbiology 5: 27-33, 2020. (JAN 2020)
  17. Yamamoto M, Ichinohe T, Watanabe A, Kobayashi A, Zhang R, Song J, Kawaguchi Y, Matsuda Z, Inoue JI. The Antimalarial compound atovaquone inhibits Zika and Dengue virus infection by blocking E protein-mediated membrane fusion. Viruses 12 (12), 1475, 2020. (DEC 2020)
  18. Yamamoto M, Kiso M, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Imai M, Takeda M, Kinoshita N, Ohmagari N, Gohda J, Semba K, Matsuda Z, Kawaguchi Y, Kawaoka Y, Inoue JI. The anticoagulant nafamostat potently inhibits SARS-CoV-2 infection in vitro: an existing drug with multiple possible therapeutic effects. BioRxiv doi: https://doi.org/10.1101/2020.04.22.054981, 2020. (APR 2020) https://www.biorxiv.org/content/10.1101/2020.04.22.054981v1
  19. Nakamura T, Hashikawa C, Okabe K, Yokote Y, Chirifu M, Toma-Fukai S, Nakamura N, Matsuo M, Kamikariya M, Okamoto Y, Gohda J, Akiyama T, Semba K, Ikemizu S, Ostuka M, Inoue JI, Yamagata Y. Structural analysis of TIFA: Insight into TIFA-dependent signal transduction in innate Immunity. Sci Rep 10(1): 5152, 2020. (MAR 2020)
  20. Kandeel M, Yamamoto M, Al-Taher A, Watanabe A, Oh-Hashi K, Park BK, Kwon HJ, Inoue JI, Al-Nazawi M. Small molecule inhibitors of middle east respiratory syndrome coronavirus fusion by targeting cavities on heptad repeat trimers. Biomol Ther (Seoul) doi:10.4062/biomolther.2019.202., 2020. (MAR 2020)
  21. Koyanagi N, Kawaguchi Y. Evasion of the cell-mediated immune response by alphaherpesviruses. Viruses12: 1354. (NOV 2020)
  22. Arii J, Fukui A, Shimanaka Y, Kono N, Arai H, Maruzuru Y, Koyanagi N, Kato A, Mori Y, Kawaguchi Y. Role of phosphatidyl-ethanolamine biosynthesis in herpes simplex virus 1 infected cells on progeny virus morphogenesis in the cytoplasm and on viral pathogenicity in vivo. J Virol, 94: e01572-20. (NOV 2020)
  23. Shirahama S, Onoguchi-Mizutani R, Kawata K, Taniue K, Miki A, Kato A, Kawaguchi Y, Tanaka R, Kaburaki T, Kawashima H, Urade Y, Aihara M, Akimitsu N. Long noncoding RNA U90926 is crucial for herpes simplex virus type 1 proliferation in murine retinal photoreceptor cells. Sci Rep 10(1): 19406. (NOV 2020)
  24. Arii J, Maeda F, Maruzuru Y, Koyanagi N, Kato A, Mori Y, Kawaguchi Y. ESCRT-III controls nuclear envelope deformation induced by progerin. Sci Rep 10: 18877, 2020. (NOV2020)
  25. Kato A, Adachi S, Kawano S, Takeshima K, Watanabe M, Kitazume S, Sato R, Kusano H, Koyanagi N, Maruzuru Y, Arii J, Hatta T, Natsume T, Kawaguchi Y. Identification of a herpes simplex virus 1 gene encoding neurovirulence factor by chemical proteomics. Nat Commun 11: 4894, 2020. (SEP 2020)
  26. Shibazaki M, Kato A, Takeshima K, Ito J, Suganami M, Koyanagi N, Maruzuru Y, Sato K, Kawaguchi Y. Phosphoregulation of a conserved herpesvirus tegument protein by a virally encoded protein kinase in viral pathogenicity and potential linkage between its evolution and viral phylogeny. J Virol 94: e01055-20, 2020. (AUG 2020)
  27. Moriyama M, Nagai M, Maruzuru Y, Koshiba T, Kawaguchi Y, Ichinohe T. Influenza virus-induced oxidized DNA activates inflammasomes. iScience 23: 101270, 2020. (JUN 2020)
  28. Hayashi Y, Suzuki H, Nakajima W, Uehara I, Tanimura A, Himeda T, Koike S, Katsuno T, Kitajiri S, Koyanagi N, Kawaguchi Y, Onomoto K, Kato H, Yoneyama M, Fujita T, Tanaka N. Cochlear supporting cells function as macrophage-like cells and protect audiosensory receptor hair cells from pathogens. Sci Rep 10: 6740, 2020. (APR 2020)

2019

  1. Kuwahara T, Yamayoshi S, Noda T, Kawaoka Y. G protein pathway suppressor 1 promotes influenza virus polymerase activity by activating the NF-ホコB signaling pathway. Mbio 10(6): e02867-19, 2019. (DEC2019)
  2. Kiso M, Yamayoshi S, Furusawa Y, Kawaoka Y. Treatment of Highly Pathogenic H7N9 Virus-Infected Mice with Baloxavir Marboxil. Viruses 11(11): 1066, 2019. (NOV 2019)
  3. Arikata M, Itoh Y, Shichinohe S, Nakayama M, Ishigaki H, Kinoshita T, Le MQ, Kawaoka Y, Ogasawara K, Shimizu T. Efficacy of clarithromycin against H5N1 and H7N9 avian influenza a virus infection in cynomolgus monkeys. Antiviral Res 171: 104591, 2019. (NOV 2019)
  4. Matsuzawa Y, Iwatsuki-Horimoto K, Nishimoto Y, Abe Y, Fukuyama S, Hamabata T, Okuda M, Go Y, Watanabe T, Imai M, Arai Y, Fouchier RAM, Yamayoshi S, Kawaoka Y. Antigenic change in human influenza A(H2N2) viruses detected by using human plasma from aged and younger adult individuals. Viruses 11(11): 978, 2019. (OCT 2019)
  5. Feldmann F, Kobasa D, Embury-Hyatt C, Grolla A, Taylor T, Kiso M, Kakugawa S, Gren J, Jones SM, Kawaoka Y, Feldmann H. Oseltamivir is effective against 1918 influenza virus infection of macaques but vulnerable to escape. mBio 10: e02059-19, 2019. (OCT 2019)
  6. Furusawa Y, Yamada S, Lopes TJS, Dutta J, Khan Z, Kriti D, van Bekel H, Kawaoka Y. Influenza virus polymerase mutation stabilizes a foreign gene inserted into the virus genome by enhancing the transcription/replication efficiency of the nodified segment. mBio 10: e01794-19, 2019. (OCT 2019)
  7. Sakai-Tagawa Y, Yamayoshi S, Kawaoka Y. Sensitivity of commercially available influenza rapid diagnostic tests in the 2018-2019 influenza season. Front Microbiol 10: 2342, 2019. (OCT 2019)
  8. Ujie M, Takada K, Kiso M, Sakai-Tagawa Y, Ito M, Nakamura K, Watanabe S, Imai M, Kawaoka Y. Long-term culture of human lung adenocarcinoma A549 cells enhances the replication of human influenza A viruses. J Gen Virol 100: 1345-1349, 2019. (OCT 2019)縲€
  9. Yamada S, Yasuhara A, Kawaoka Y. Soluble recombinant hemagglutinin protein of H1N1pdm09 influenza virus elicits cross-protection against a lethal H5N1 challenge in mice. Front Microbiol 10: 2031, 2019. (SEP 2019)縲€
  10. Feng H, Nakajima N, Wu L, Yamashita M, Lopes TJS, Tsuji M, Hasegawa H, Watanabe T, Kawaoka Y. A glycolipid adjuvant, 7DW8-5, enhances the protective immune response to the current split influenza vaccine in mice. Front Microbiol 10: 2157, 2019. (SEP 2019)縲€
  11. Feng H, Yamashita M, Wu L, Lopes TJS, Watanabe T, Kawaoka Y. Food additives as novel influenza vaccine adjuvants. Vaccines 7: 127, 2019. (SEP 2019)縲€
  12. Liang L, Jiang L, Li J, Zhao Q, Wang J, He X, Huang S, Wang Q, Zhao Y, Wang G, Sun N, Deng G, Shi J, Tian G, Zeng X, Jiang Y, Liu L, Liu J, Chen P, Bu Z, Kawaoka Y, Chen H, Li C. Low polymerase activity attributed to PA drives the acquisition of the PB2 E627K mutation of H7N9 avian influenza virus in mammals. MBio 10: e01162-19, 2019. (JUN 2019)
  13. Zhong G, Fan S, Lopes TJS, Le MQ, van Bakel H, Dutta J, Smith GJD, Jayakumar J, Nguyen HLK, Hoang PVM, Halfmann P, Hatta M, Su YCF, Neumann G, Kawaoka Y. Isolation of highly pathogenic H5N1 influenza viruses in 2009-2013 in vietnam. Front Microbiol 10: 1411, 2019. (JUN 2019)
  14. Okuda M, Yamayoshi S, Uraki R, Ito M, Hamabata T, Kawaoka Y. Subclade 2.2.1-specific human monoclonal antibodies that recognize an epitope in antigenic site A of influenza A(H5) virus HA detected between 2015 and 2018. Viruses 11: E321, 2019. (APR 2019)
  15. Takada K, Kawakami C, Fan S, Chiba S, Zhong G, Gu C, Shimizu K, Takasaki S, Sakai-Tagawa Y, Lopes TJS, Dutta J, Khan Z, Kriti D, van Bakel H, Yamada S, Watanabe T, Imai M, Kawaoka Y. A humanized MDCK cell line for the efficient isolation and propagation of human influenza viruses. Nat Microbiol 4: 1268-1273, 2019. (APR 2019)
  16. Yasuhara A, Yamayoshi S, Kiso M, Sakai-Tagawa Y, Koga M, Adachi E, Kikuchi T, Wang IH, Yamada S, Kawaoka Y. Antigenic drift originating from changes to the lateral surface of the neuraminidase head of influenza A virus. Nat Microbiol 4:1024-1034, 2019. (MAR 2019)
  17. Oishi K, Yamayoshi S, Kawaoka Y. Identification of amino acid residues in influenza A virus PA-X That contribute to enhanced shutoff activity. Front Microbiol 10: 432, 2019. (MAR 2019)
  18. Kawakami C, Yamayoshi S, Akimoto M, Nakamura K, Miura H, Fujisaki S, Pattinson DJ, Shimizu K, Ozawa H, Momoki T, Saikusa M, Yasuhara A, Usuku S, Okubo I, Toyozawa T, Sugita S, Smith DJ, Watanabe S, Kawaoka Y. Genetic and antigenic characterisation of influenza A(H3N2) viruses isolated in Yokohama during the 2016/17 and 2017/18 influenza seasons. Euro Surveill 24: 1800467, 2019. (FEB 2019)
  19. Ito M, Yamayoshi S, Murakami K, Saito K, Motojima A, Nakaishi K, Kawaoka Y. Viruses. Characterization of mouse monoclonal antibodies against the HA of A(H7N9) influenza virus. Viruses 11: E149, 2019. (FEB 2019)
  20. Feng H, Yamashita M, da Silva Lopes TJ, Watanabe T, Kawaoka Y. Injectable excipients as novel influenza vaccine adjuvants. Front Microbiol 10: 19, 2019. (JAN 2019)
  21. Gu C, Zeng X, Song Y, Li Y, Liu L, Kawaoka Y, Zhao D, Chen H. Glycosylation and an amino acid insertion in the head of hemagglutinin independently affect the antigenic properties of H5N1 avian influenza viruses. Sci China Life Sci 62: 76-83, 2019. (JAN 2019)
  22. Yamamoto M, Du Q, Song J, Wang H, Watanabe A, Tanaka Y, Kawaguchi Y, Inoue JI, Matsuda Z. Cell-cell and virus-cell fusion assay-based analyses of alanine insertion mutants in the distal ホア9 portion of the JRFL gp41 subunit from HIV-1. J Biol Chem 294(14): 5677-5687. doi: 10.1074/jbc.RA118.004579, 2019. (APR 2019)
  23. Hatanaka N, Seki T, Inoue J, Tero A, Suzuki T. Critical roles of IホコBホア and RelA phosphorylation in transitional oscillation in NF-ホコB signaling module. J Theor Biol 462: 479-489. doi: 10.1016/j.jtbi.2018.11.023, 2019. (FEB 2019)縲€
  24. Joo S, Suwanto A, Sato A, Nakahashi-Ouchida R, Mori H, Uchida Y, Sato S, Kurashima Y, Yuki Y, Fujihashi K, Kawaguchi Y, Kiyono H. A role for the CCR5-CCL5 interaction in the preferential migration of HSV-2-specific effector cells to the vaginal mucosa upon nasal immunization. Mucosal Immunol 12: 1391-1403, 2019. (NOV 2019)
  25. Takeshima K, Arii J, Maruzuru Y, Koyanagi N, Kato A, Kawaguchi Y. Identification of the capsid binding site in the herpes simplex virus 1 nuclear egress complex and its role in viral primary envelopment and replication. J Virol 93: e01290-19, 2019. (OCT 2019)
  26. J Arii, K Takeshima, Y Maruzuru, N Koyanagi, A Kato, Y Kawaguchi. Roles of the interhexamer contact site for hexagonal lattice formation of herpes simplex virus 1 nuclear egress complex in viral primary envelopment and replication. J Virol 93: e00498-19, 2019. (MAY 2019)

2018

  1. Yamayoshi S, Yasuhara A, Ito M, Uraki R, Kawaoka Y. Differences in the ease with which mutant viruses escape from human monoclonal antibodies against the HA stem of influenza A virus. J Clin Virol 108: 105-111, 2018. (NOV 2018)
  2. Yasuhara A, Yamayoshi S, Ito M, Kiso M, Yamada S, Kawaoka Y. Isolation and characterization of human monoclonal antibodies that recognize the influenza A(H1N1)pdm09 virus hemagglutinin receptor-binding site and rarely yield escape mutant viruses. Front Microbiol 9: 2660, 2018. (NOV 2018)
  3. Hatta M, Zhong G, Chiba S, Lopes TJS, Neumann G, Kawaoka Y. Effectiveness of whole, inactivated, low pathogenicity influenza A(H7N9) vaccine against antigenically distinct, highly pathogenic H7N9 virus. Emerg Infect Dis 24:1910-1913, 2018. (OCT 2018)
  4. Chiba S, Hill-Batorski L, Neumann G, Kawaoka Y. The cellular DExD/H-Box RNA helicase UAP56 co-localizes with the influenza A virus NS1 protein. Front Microbiol 9: 2192, 2018. (SEP 2018)
  5. Wu NC, Yamayoshi S, Ito M, Uraki R, Kawaoka Y, Wilson IA. Recurring and adaptable binding motifs in broadly neutralizing antibodies to influenza virus are encoded on the D3-9 segment of the Ig gene. Cell Host Microbe 24: 569-578, 2018. (OCT 2018)
  6. Imai H, Dinis JM, Zhong G, Moncla LH, Lopes TJS, McBride R, Thompson AJ, Peng W, Le MTQ, Hanson A, Lauck M, Sakai-Tagawa Y, Yamada S, Eggenberger J, O'Connor DH, Suzuki Y, Hatta M, Paulson JC, Neumann G, Friedrich TC, Kawaoka Y. Diversity of influenza A(H5N1) Viruses in infected humans, Northern Vietnam, 2004-2010. Emerg Infect Dis 24: 1128-1238, 2018. (JUL 2018)
  7. Ueki H, Wang IH, Fukuyama S, Katsura H, da Silva Lopes TJ, Neumann G, Kawaoka Y. In vivo imaging of the pathophysiological changes and neutrophil dynamics in influenza virus-infected mouse lungs. Proc Natl Acad Sci U S A 115: E6622-E6629, 2018. (JUL 2018)
  8. Oishi K, Yamayoshi S, Kozuka-Hata H, Oyama M, Kawaoka Y. N-terminal acetylation by NatB is required for the shutoff activity of influenza A virus PA-X. Cell Rep 24(4): 851-860, 2018. (JUL 2018)
  9. Furusawa Y, Yamada S, Kawaoka Y. Host factor nucleoporin 93 is involved in the nuclear export of influenza virus RNA. Front Microbiol 9: 1675, 2018. (JUL 2018)
  10. Iwatsuki-Horimoto K, Shi J, Wang X, Sakai-Tagawa Y, Ito M, Murakami K, da Silva Lopes TJ, Nakaishi K, Yamayoshi S, Watabe S, Chen H, Kawaoka Y. Development of an influenza rapid diagnostic kit specific for the H7 subtype. Front Microbiol 9: 1346, 2018. (JUN 2018)
  11. Sammaibashi S, Yamayoshi S, Kawaoka Y. Strain-specific contribution of eukaryotic elongation factor 1 gamma to the translation of influenza A virus proteins. Front Microbiol 9: 1446, 2018. (JUN 2018)
  12. Iwatsuki-Horimoto K, Nakajima N, Kiso M, Takahashi K, Ito M, Inoue T, Horiuchi M, Okahara N, Sasaki E, Hasegawa H, Kawaoka Y. The marmoset as an animal model of influenza: infection with A(H1N1)pdm09 and highly pathogenic A(H5N1) viruses via the conventional or tracheal spray route. Front Microbiol 9: 844, 2018. (MAY 2018)
  13. Matsui K, Ozawa M, Kiso M, Yamashita M, Maekawa T, Kubota M, Sugano S, Kawaoka Y. Stimulation of alpha2-adrenergic receptors impairs influenza virus infection. Sci Rep 8: 4631, 2018. (MAR 2018)
  14. Soni P, Yasuhara A, Takenaga T, Iwatsuki-Horimoto K, Uraki R, Ito M, Sasaki T, Ikuta K, Yamayoshi S, Kawaoka Y. Evaluation of the fusion partner cell line SPYMEG for obtaining human monoclonal antibodies against influenza B virus. J Vet Med Sci 80: 1020-1024, 2018. (JUN 2018)
  15. Maemura T, Fukuyama S, Sugita Y, Lopes TJS, Nakao T, Noda T, Kawaoka Y. Lung-derived exosomal miR-483-3p regulates the innate immune response to influenza virus infection. J Infect Dis 217: 1372-1382, 2018. (APR 2018)
  16. Yamayoshi S, Kiso M, Yasuhara A, Ito M, Shu Y, Kawaoka Y. Enhanced replication of highly pathogenic influenza A(H7N9) virus in humans. Emerg Infect Dis 24: 746-750, 2018. (APR 2018)
  17. Watanabe T, Iwatsuki-Horimoto K, Kiso M, Nakajima N, Takahashi K, Lops TJS, Ito M, Fukuyama S, Hasegawa H, Kawaoka Y. Experimental infection of Cynomolgus Macaques with highly pathogenic H5N1 influenza virus through the aerosol route. Sci Rep 8: 4801, 2018. (MAR 2018)
  18. Kiso M, Lopes TJS, Yamayoshi S, Ito M, Yamashita M, Nakajima N, Hasegawa H, Neumann G, Kawaoka Y. Combination therapy with neuraminidase and polymerase inhibitors in nude mice infected with influenza virus. J Infect Dis 217: 887-896, 2018. (MAR 2018)
  19. Iwatsuki-Horimoto K, Nakajima N, Ichiko Y, Sakai-Tagawa Y, Noda T, Hasegawa H, Kawaoka Y. Syrian hamster as an animal model for the study of human influenza virus infection. J Virol 92: e01693-17, 2018. (JAN 2018)
  20. Zhong G, Le MQ, Lopes TJS, Halfmann P, Hatta M, Fan S, Neumann G, Kawaoka Y. Mutations in the PA protein of avian H5N1 influenza viruses affect polymerase activity and mouse virulence. J Virol 92: e01557-17, 2018. (JAN 2018)
  21. Yamayoshi S, Ito M, Uraki R, Sasaki T, Ikuta K, Kawaoka Y. Human protective monoclonal antibodies against the HA stem of group 2 HAs derived from an H3N2 virus-infected human. J Infect, in press. J Infect 76: 177-185, 2018. (FEB 2018)
  22. Oishi K, Yamayoshi S, Kawaoka Y. Identification of novel amino acid residues of influenza virus PA-X that are important for PA-X shutoff activity by using yeast. Virology 516: 71-75, 2018. (JAN 2018)
  23. Hatta M, Zhong G, Gao Y, Nakajima N, Fan S, Chiba S, Deering KM, Ito M, Imai M, Kiso M, Nakatsu S, Lopes TJ, Thompson AJ, McBride R, Suarez DL, Macken CA, Sugita S, Neumann G, Hasegawa H, Paulson JC, Toohey-Kurth KL, Kawaoka Y. Characterization of a feline influenza A(H7N2) virus. Emerg Infect Dis 24: 75-86, 2018. (JAN 2018)
  24. Liu D, Wang H, Yamamoto M, Song J, Zhang R, Du Q, Kawaguchi Y, Inoue JI, Matsuda Z. Six-helix bundle completion in the distal C-terminal heptad repeat region of gp41 is required for efficient human immunodeficiency virus type 1 infection. Retrovirology 15(1): 27. doi: 10.1186/s12977-018-0410-9, 2018 (APR 2018)
  25. Gohda J, Suzuki K, Liu K, Xie X, Takeuchi H, Inoue J, Kawaguchi Y, Ishida T. BI-2536 and BI-6727, dual Polo-like kinase/bromodomain inhibitors, effectively reactivate latentHIV-1. Scientific Reports 8 (1): 3521. doi: 10.1038/s41598-018-21942-5, 2018. (FEB 2018)
  26. Sato R, Kato A, Chimura T, Saitoh S-I, Shibata T, Murakami Y, Fukui R, Liu K, Zhang Y, Arii J, Sun-Wada G-H, Wada Y, Ikenoue T, Barber G N, Manabe T, Kawaguchi Y, Miyake K. Combating herpesvirus encephalitis by potentiating a TLR3-mTORC2 axis. Nat Immunol 19: 1071-1082, 2018. (OCT 2018)
  27. Arii J, Watanabe M, Maeda F, Tokai-Nishizumi N, Chihara T, Miura M, Maruzuru Y, Koyanagi N, Kato A, Kawaguchi Y. ESCRT-III mediates budding across the inner nuclear membrane and regulates its integrity. Nat Commun 9: 3379, 2018. (AUG 2018)
  28. Kato A, Oda S, Watanabe M, Oyama M, Kozuka-Hata H, Koyanagi N, Maruzuru Y, Arii J, Kawaguchi Y. Roles of the phosphorylation of herpes simplex virus 1 UL51 at a specific site in viral replication and pathogenicity. J Virol 92: e01035-18, 2018. (AUG 2018)
  29. Koyanagi N, Kato A, Takeshima K, Maruzuru Y, Kozuka-Hata H, Oyama M, Arii J, Kawaguchi Y. Regulation of herpes simplex virus 2 protein kinase UL13 by phosphorylation and its role in viral pathogenesis. J Virol 92: e00807-18, 2018. (AUG 2018)
  30. Maruzuru Y, Ichinohe T, Sato R, Miyake K, Okano T, Suzuki T, Koshiba T, Koyanagi N, Tsuda S, Watanabe M, Arii J, Kato A, Kawaguchi Y. Herpes simplex virus 1 VP22 inhibits AIM2-dependent inflammasome activation to enable efficient viral replication. Cell Host & Microbe 23: 254-265, 2018 (FEB 2018)

2017

  1. Yasuhara A, Yamayoshi S, Soni P, Takenaga T, Kawakami C, Takashita E, Sakai-Tagawa Y, Uraki R, Ito M, Iwatsuki-Horimoto K, Sasaki T, Ikuta K, Yamada S, Kawaoka Y. Diversity of antigenic mutants of influenza A(H1N1)pdm09 virus escaped from human monoclonal antibodies. Sci Rep 7: 17735, 2017. (DEC 2017)
  2. Imai M, Watanabe T, Kiso M, Nakajima N, Yamayoshi S, Iwatsuki-Horimoto K, Hatta M, Yamada S, Ito M, Sakai-Tagawa Y, Shirakura M, Takashita E, Fujisaki S, McBride R, Thompson AJ, Takahashi K, Maemura T, Mitake H, Chiba S, Zhong G, Fan S, Oishi K, Yasuhara A, Takada K, Nakao T, Fukuyama S, Yamashita M, Lopes TJS, Neumann G, Odagiri T, Watanabe S, Paulson JC, Hasegawa H, Kawaoka Y. Characterization of a highly pathogenic avian H7N9 influenza virus isolated from an infected human. Cell Host&Microbe 22: 615-626, 2017. (NOV 2017)
  3. Sakai-Tagawa Y, Yamayoshi S, Kawakami C, Le MQ, Uchida Y, Saito T, Nidom CA, Humaira I, Toohey-Kurth K, Arafa AS, Liu MT, Shu Y, Kawaoka Y. Reactivity and sensitivity of commercially available influenza rapid diagnostic tests in Japan. Sci Rep 7: 14483, 2017. (NOV 2017)
  4. Kiso M, Iwatsuki-Horimoto K, Yamayoshi S, Uraki R, Ito M, Nakajima N, Yamada S, Imai M, Kawakami E, Tomita Y, Fukuyama S, Itoh Y, Ogasawara K, Lopes TJS, Watanabe T, Moncla LH, Hasegawa H, Friedrich TC, Neumann G, Kawaoka Y. Emergence of oseltamivir-resistant H7N9 influenza viruses in immunosuppressed cynomolgus macaques. J Infect Dis 216: 582-593, 2017. (SEP 2017)
  5. Ui H, Yamayoshi S, Uraki R, Kiso M, Oishi K, Murakami S, Mimori S, Kawaoka Y. Evaluation of seasonal influenza vaccines for H1N1pdm09 and type B viruses based on a replication-incompetent PB2-KO virus. Vaccine 35: 1892-1897, 2017. (APR 2017)
  6. Yamayoshi S, Uraki R, Ito M, Kiso M, Nakatsu S, Yasuhara A, Oishi K, Sasaki T, Ikuta K, Kawaoka Y. A Broadly reactive human anti-hemagglutinin stem monoclonal antibody that inhibits influenza A virus particle release. EBioMedicine 17: 182-191, 2017. (MAR 2017)
  7. Zhao D, Liang L, Wang S, Nakao T, Li Y, Liu L, Guan Y, Fukuyama S, Bu Z, Kawaoka Y, Chen H. Glycosylation of the HA protein of H5N1 influenza virus increases its virulence in mice by exacerbating the host immune response. J Virol 91: e02215-02216, 2017. (MAR 2017)
  8. Nakayama M, Itoh Y, Shichinohe S, Nakabayashi R, Ishigaki H, Sakoda Y, Le QM, Kawaoka Y, Kida H, Ogasawara K. Potential risk of repeated nasal vaccination that induces allergic reaction with mucosal IgE and airway eosinophilic infiltration in cynomolgus macaques infected with H5N1 highly pathogenic avian influenza virus. Vaccine 35: 1008-1017, 2017. (FEB 2017)
  9. Koyanagi N, Imai T, Shindo K, Sato A, Fujii W, Ichinohe T, Takemura N, Kakuta S, Uematsu S, Kiyono H, Maruzuru Y, Arii J, Kato A, Kawaguchi Y. Herpes simplex virus-1 evasion of CD8+ T cell accumulation contributes to viral encephalitis. J Clin Invest 127: 3784-3795, 2017. (OCT 2017)
  10. Kobayashi R, Kato A, Sagara H, Watanabe M, Maruzuru Y, Koyanagi N, Arii J, Kawaguchi Y. Herpes simplex virus 1 small capsomere-interacting protein VP26 regulates nucleocapsid maturation. J Virol 91: e01068-17, 2017. (SEP 2017)
  11. Akkina R, Ellerbrok H, Hall W, Hasegawa H, Kawaguchi Y, Kleanthous H, McSweegan E, Mercer N, Romanowski V, Sawa H, Vahlne A. 2016 international meeting of the global virus network. Antiviral Res 142: 21-29, 2017. (JUN 2017)
  12. Maeda F, Arii J, Hirohata Y, Maruzuru Y, Koyanagi N, Kato A, Kawaguchi Y. Herpes simplex virus 1 UL34 protein regulates the global architecture of the endoplasmic reticulum in infected cells. J Virol 91: e000271-17, 2017. (JUN 2017)

2016

  1. Arafa A-S, Yamada S, Imai M, Watanabe T, Yamayoshi S, Iwatsuki-Horimoto K, Kiso M, Sakai-Tagawa Y, Ito M, Imamura T, Nakajima N, Takahashi K, Zhao D, Oishi K, Yasuhara A, Macken C, Zhong G, Hanson A, Fan S, Ping J, Hatta M, Lopes T, Suzuki Y, El-Husseiny M, Selim A, Hagag N, Soliman M, Neumann G, Hasegawa H, Kawaoka Y. Risk assessment of recent Egyptian H5N1 influenza viruses. Sci Rep 6:38388, 2016. (DEC 6, 2016・・/li>
  2. Ando T, Yamayoshi S, Tomita Y, Watanabe S, Watanabe T, Kawaoka Y. The host protein CLUH participates in the subnuclear transport of influenza virus ribonucleoprotein complexes. Nat Microbiol 1:16062, 2016. (AUG 2016)
  3. Li C, Hatta M, Burke DF, Ping J, Zhang Y, Ozawa M, Taft AS, Das SC, Hanson AP, Song J, Imai M, Wilker PR, Watanabe T, Watanabe S, Ito M, Iwatsuki-Horimoto K, Russell CA, James SL, Skepner E, Maher EA, Neumann G, Klimov A, Kelso A, McCauley J, Wang D, Shu Y, OdagiriT, Tashiro M, Xu X, Wentworth DE, Katz JM, Cox NJ, Smith DJ, Kawaoka Y. Selection of antigenically advanced variants of seasonal influenza viruses. Nat Microbiol 1:16058, 2016. (JUN 2016)
  4. Moncla LH, Zhong G, Nelson CW, Dinis JM, Mutschler J, Hughes AL, Watanabe T, Kawaoka Y, Friedrich TC. Selective bottlenecks shape evolutionary pathways taken during mammalian adaptation of a 1918-like avian influenza virus. Cell Host Microbe 19:169-180, 2016. (FEB 10, 2016)
  5. Katsura H, Fukuyama S, Watanabe S, Ozawa M, Neumann G, Kawaoka Y. Amino acid changes in PB2 and HA affect the growth of a recombinant influenza virus expressing a fluorescent reporter protein. Sci Rep 6:19933,縲€2016. (FEB 5, 2016)
  6. Yang H, Chen Y, Qiao C, He X, Zhou H, Sun Y, Yin H, Meng S, Liu L, Zhang Q, Kong H, Gu C, Li C, Bu Z, Kawaoka Y, Chen H. Prevalence, genetics, and transmissibility in ferrets of Eurasian avian-like H1N1 swine influenza viruses. Proc Natl Acad Sci USA 113:392-397, 2016. (JAN 2016)
  7. Yamayoshi S, Watanabe M, Goto H, Kawaoka Y. Identification of A Novel Viral Protein Expressed from the PB2 Segment of Influenza A Virus. J Virol 90:444-456, 2016. (JAN 2016)
  8. Yamamoto M, Matsuyama S, Li X, Takeda M, Kawaguchi Y, Inoue J, Matsuda Z. Identification of nafamostat as a potent inhibitor of Middle East respiratory syndrome (MERS) corona virus S-mediated membrane fusion using the split protein-based cell-cell fusion assay. Antimicrob Agents Chemother 60:6532-6539, 2016. (DOI:10.1128/AAC.01043-16) (Aug 22, 2016)
  9. J. Arii, K. Shindo, N. Koyanagi, A. Kato and Y. Kawaguchi. Multiple Roles of the Cytoplasmic Domain of Herpes Simplex Virus 1 Envelope Glycoprotein D in Infected Cells. J Virol 90:10170-10181, 2016. (NOV 2016)
  10. S. Oda, J. Arii, N. Koyanagi, A. Kato, and Y. Kawaguchi. Interaction between Herpes Simplex Virus 1 Tegument Proteins UL51 and UL14 and Its Role in Virion Morphogenesis. J Virol 90:8754-8767, 2016. (OCT 2016)
  11. N. Maeda, A. Furukawa, K. Kakita, M. Anada, S. Hashimoto, S. Matsunaga, K. Kuroki, T. Ose, A. Kato, J. Arii, Y. Kawaguchi, H. Arase and K. Maenaka. Rapid screening by cell-based fusion assay for identifying novel antivirals of 5 glycoprotein B-mediated herpes simplex virus type 1 infection. Biol. Pharm. Bull 39:1897-1902, 2016. (JUL 2016)
  12. Y. Maruzuru, N. Koyanagi, N. Takemura, S. Uematsu, D. Matsubara, Y. Suzuki, J. Arii, A. Kato, and Y. Kawaguchi. p53 is a Host Cell Regulator during Herpes Simplex Encephalitis. J Virol 90: 6738-6745, 2016. (AUG 2016)
  13. A. Kato, T. Ando, S. Oda, M. Watanabe, N. Koyanagi, J. Arii and Y. Kawaguchi. Roles of Us8A and its phosphorylation mediated by Us3 in herpes simplex virus 1 pathogenesis. J Virol 90:5622-5635, 2016. (JUN 2016)
  14. Y. Sato, A. Kato, Y. Maruzuru, M. Oyama, H. Kozuka-Hata, J. Arii and Y. Kawaguchi. (2016) Cellular Transcriptional Coactivator RanBP10 and Herpes Simplex Virus 1 ICP0 Interact and Synergistically Promote Viral Gene Expression and Replication. J. Virol 90:3173-3186, 2016. (MAR 2016)
  15. Y. Sato, A. Kato, J. Arii, N. Koyanagi, H. Kozuka-Hata, M. Oyama and Y. Kawaguchi. (2016) Ubiquitin-Specific Protease 9X in Host Cells Interacts with Herpes Simplex Virus 1 ICP0. J. Vet. Med. Sci. 78:405-410, 2016. (MAR 2016)
  16. Shindo K, Kato A, Koyanagi N, Sagara H, Arii J, and Kawaguchi Y. Characterization of a herpes simplex virus 1 (HSV-1) chimera in which the Us3 protein kinase gene is replaced with the HSV-2 Us3 gene. J Virol 90:457-473, 2016. (JAN 2016)

2015

  1. Hanson A, Imai M, Hatta M, McBride R, Imai H, Taft A, Zhong G, Watanabe T, Suzuki Y, Neumann G, Paulson JC, Kawaoka Y. Identification of Stabilizing Mutations in an H5 HA Influenza Virus Protein. J Virol 90:2981-2992, 2015. (DEC 30, 2015)
  2. Zhao D, Fukuyama S, Sakai-Tagawa Y, Takashita E, Shoemaker JE, Kawaoka Y. C646, a novel p300/CREB-binding protein-specific inhibitor of histone acetyltransferase, attenuates influenza A virus infection. Antimicrob Agents Chemother 60:1902-1906, 2015. (DEC 28, 2015)
  3. Uraki R, Piao Z, Akeda Y, Iwatsuki-Horimoto K, Kiso M, Ozawa M, Oishi K, Kawaoka Y. A bivalent vaccine based on a PB2-knockout influenza virus protects mice from secondary pneumococcal pneumonia. J Infect Dis 212:1939-1948, 2015. (DEC 15, 2015)
  4. Uraki R, Piao Z, Akeda Y, Iwatsuki-Horimoto K, Kiso M, Ozawa M, Oishi K, Kawaoka Y. A bivalent vaccine based on a PB2-knockout influenza virus protects mice from secondary pneumococcal pneumonia. J Infect Dis縲€212(12):1939-1948, 2015. (DEC 15, 2015)
  5. Forero A, Tisoncik-Go J, Watanabe T, Zhong G, Hatta M, Tchitchek N, Selinger C, Chang J, Barker K, Morrison J, Berndt JD, Moon RT, Josset L, Kawaoka Y, Katze MG. The 1918 PB2 protein enhances virulence through the disruption of inflammatory and Wnt-mediated signaling in mice. J Virol 90:2240-2253, 2015. (DEC 09, 2015)
  6. Zhao D, Fukuyama S, Yamada S, Lopes TJ, Maemura T, Katsura H, Ozawa M, Watanabe S, Neumann G, Kawaoka Y. Molecular determinants of virulence and stability of a reporter-expressing H5N1 influenza A virus. J Virol 89:11337-11346, 2015. (NOV 2015)
  7. Ping J, Lopes T.J.S, Nidom CA, Ghedin E, Macken CA, Fitch A, Imai M, Maher EA, Neumann G, Kawaoka Y. Development of high-yield influenza A virus vaccine viruses. Nat Commun 6:8148, 2015. (SEP 2015・・/li>
  8. Oishi K, Yamayoshi S, Kawaoka Y. Mapping of a region of the PA-X protein of influenza A virus that is important for its shut-off activity. J Virol 89:8661-8665, 2015. (AUG 2015)
  9. Shoemaker JE, Fukuyama S, Eisfeld AJ, Zhao D, Kawakami E, Sakabe S, Maemura T, Gorai T, Katsura H, Muramoto Y, Watanabe S, Watanabe T, Fuji K, Matsuoka Y, Kitano H, Kawaoka Y. An ultrasensitive mechanism regulates influenza virus-induced inflammation. PLoS Pathog e1004856, 2015. (JUN 2015)
  10. Taft AS, Ozawa M, Fitch A, Depasse JV, Halfmann PJ, Hill-Batorski L, Hatta M, Friedrich TC, Lopes TJS, Maher EA, Ghedin E, Macken CA, Neumann B, Kawaoka Y. Identification of mammalian-adapting mutations in the polymerase complex of an avian H5N1 influenza virus. Nat Commun 6:7491, 2015. (JUN 2015)
  11. Yamaji R, Yamada S, Le MQ, Li C, Chen H, Qurnianingsih E, Nidom CA, Ito M, Sakai-Tagawa Y, Kawaoka Y. Identification of PB2 mutations responsible for the efficient replication of H5N1 influenza viruses in human lung epithelial cells. J Virol 89:3947-3956, 2015. (APR 2015)
  12. Yamaji R, Yamada S, Le MQ, Ito M, Sakai-Tagawa Y, Kawaoka Y. Mammalian adaptive mutations of the PA protein of highly pathogenic avian H5N1 influenza virus. J Virol 89:4117-4125, 2015. (APR 2015)
  13. Fukuyama S, Katsura H, Zhao D, Ozawa M, Ando T, Shoemaker JE, Ishikawa I, Yamada S, Neumann G, Watanabe S, Kitano H, Kawaoka Y. Multi-spectral fluorescent reporter influenza viruses (Color-flu) as powerful tools for in vivo studies. Nat Commun, 6:6600, 2015. (MAR 2015)
  14. Yamayoshi S, Fukuyama S, Yamada S, Zhao D, Murakami S, Uraki R, Watanabe T, Tomita Y, Neumann G, Kawaoka Y. Amino acids substitutions in the PB2 protein of H7N9 influenza A viruses are important for virulence in mammalian hosts. Sci Rep 5:8039, 2015. (JAN 27, 2015)
  15. Nakane S, Iwamoto A, Matsuda Z. The V4 and V5 variable loops of HIV-1 envelope glycoprotein are tolerant to insertion of green fluorescent protein and are useful targets for labeling. J Biol Chem 290(24):15279-91, 2015. (JUN 12, 2015)
  16. Nakane S, Matsuda Z. Dual split protein (DSP) assay to monitor cell-cell membrane fusion. Methods Mol Biol 1313:229-36, 2015. (doi: 10.1007/978-1-4939-2703-6_17.) (JUN 2015)
  17. Saw WT, Matsuda Z, Eisenberg RJ, Cohen GH, Atanasiu D. Using a split luciferase assay (SLA) to measure the kinetics of cell-cell fusion mediated by herpes simplex virus glycoproteins. Methods pii:S1046-2023(15)00227-3, 2015. (doi:10.1016/j.ymeth.2015.05.021) (MAY 26, 2015)
  18. Matsuda Z. Recent advance in the structural analysis of HIV-1 envelope protein. Sci China Life Sci May;58(5):420-424, 2015.・・AY 2015)
  19. Liu C, Zhao Y, He W, Wang W, Chen Y, Zhang S, Ma Y, Gohda J, Ishida T, Walter TS, Owens RJ, Stuart DI, Ren J, Gao B. A RANKL mutant used as an inter-species vaccine for efficient immunotherapy of osteoporosis. Sci Rep 5:14150, 2015.・・EP 28, 2015・・/li>
  20. Gu L, Han Y, Li Y, Zhu T, Song X, Huang H, Yang F, Guan S, Xie J, Gohda J, Hosoya N, Kawana-Tachikawa A, Liu W, Gao GF, Iwamoto A, Li T, Ishida T. Emergence of Lamivudine-Resistant HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV and HBV in China. PLoS ONE 10(8):e0134539, 2015. (AUG 2015)
  21. Li Y, Gu L, Han Y, Xie J, Wang H, Lv W, Song X, Li Y, Iwamoto A, Ishida T, Li T. HIV-1 subtype B/B' and baseline drug resistance mutation are associated with virologic failure: a multicenter cohort study in China. J Acquir Immune Defic Syndr 68(3):289-97, 2015. (MAR 2015)
  22. Gohda J, Ma Y, Huang Y, Zhang Y, Gu L, Han Y, Li T, Gao B, Gao GF, Inoue J-i, Iwamoto A, Ishida T. HIV-1 replicates in human osteoclasts and enhances their differentiation in vitro. Retrovirology 12:12, 2015. (FEB 7, 2015)
  23. Matsuda Y, Kobayashi-Ishihara M, Fujikawa D, Ishida T, Watanabe T, Yamagishi M. Epigenetic heterogeneity in HIV-1 latency establishment. Sci Rep 5:7701, 2015.・・AN 9, 2015・・/li>
  24. Nakayama-Hosoya K, Ishida T, Youngblood B, Nakamura H, Hosoya N, Koga M, Koibuchi T, Iwamoto A, Kawana-Tachikawa A. Epigenetic repression of interleukin 2 expression in senescent CD4+ T cells during chronic HIV type 1 infection. J Infect Dis 211:28-39, 2015. (JAN 1, 2015)
  25. Liu Z, Kato A, Oyama M, Kozuka-Hata H, Arii J, Kawaguchi Y. Role of host cell p32 in herpes simplex virus 1 de-envelopment during viral nuclear egress. J Virol 89(17):8982-8998, 2015. (SEP 2015)
  26. Hirohata Y, Arii J, Liu Z, Shindo K, Oyama M, Kozuka-Hata H, Sagara H, Kato A, Kawaguchi Y. Herpes simplex virus 1 recruits CD98 heavy chain and ホイ1 integrin to the nuclear membrane for viral de-envelopment. J Virol 89(15):7799-7812, 2015. (AUG 2015)
  27. Arii J, Hirohata Y, Kato A and Kawaguchi Y. Nonmuscle myosin heavy chain IIB mediates herpes simplex virus 1 entry. J Virol 89(3):1879-1888, 2015. (FEB 2015)
  28. Kobayashi R, Kato A, Oda S, Koyanagi N, Oyama M, Kozuka-Hata H, Arii J,Kawaguchi Y. The function of the herpes simplex virus 1 small capsid protein VP26 is regulated by phosphorylation at a specific site. J Virol 89(11): 6141-6147, 2015. (JUN 2015)
  29. Hirohata Y, Kato A, Oyama M, Kozuka-Hata H, Koyanagi N, Arii J, Kawaguchi Y. Interactome analysis of herpes simplex virus 1 envelope glycoprotein H. Microbiol Immunol 59(6):331-337, 2015. (JUN 2015)
  30. Kato A, Arii J, Koyanagi Y, Kawaguchi Y. Phosphorylation of herpes simplex virus 1 dUTPase regulates viral virulence and genome integrity by compensating for low cellular dUTPase activity in the central nervous system. J Virol 89(1):241-248, 2015. (JAN 2015)

2014

  1. Fan S, Hatta M, Kim JH, Le MQ, Neumann G, Kawaoka Y. Amino Acid Changes in the Influenza A Virus PA Protein That Attenuate Avian H5N1 Viruses in Mammals. J Virol 88:13737-13746, 2014 (DEC 2014).
  2. Fan S, Hatta M, Kim JH, Halfmann P, Imai M, Macken CA, Le MQ, Nguyen T, Neumann G, Kawaoka Y. Novel residues in avian influenza virus PB2 protein affect virulence in mammalian hosts. Nat Commun 5:5021, 2014 (OCT 2014).
  3. Sakai-Tagawa Y, Ozawa M, Yamada S, Uchida Y, Saito T, Takahashi K, Sugaya N, Tashiro M, Kawaoka Y. Detection sensitivity of influenza rapid diagnostic tests. Microbiol Immunol 58:600-606, 2014 (OCT 2014).
  4. Uraki R, Das SC, Hatta M, Kiso M, Iwatsuki-Horimoto K, Ozawa M, Coban C, Ishii KJ, Kawaoka Y. Hemozoin as a novel adjuvant for inactivated whole virion influenza vaccine. Vaccine 32:5295-300, 2014 (SEP 15, 2014)
  5. Muramoto Y, Shoemaker JE, Le MQ, Itoh Y, Tamura D, Sakai-Tagawa Y, Imai H, Uraki R, Takano R, Kawakami E, Ito M, Okamoto K, Ishigaki H, Mimuro H, Sasakawa C, Matsuoka Y, Noda T, Fukuyama S, Ogasawara K, Kitano H, Kawaoka Y. Disease Severity Is Associated with Differential Gene Expression at the Early and Late Phases of Infection in Nonhuman Primates Infected with Different H5N1 Highly Pathogenic Avian Influenza Viruses. J Virol 88:8981-8997, 2014 (AUG 2014).
  6. Itoh Y, Yoshida R, Shichinohe S, Higuchi M, Ishigaki H, Nakayama M, Pham VL, Ishida H, Kitano M, Arikata M, Kitagawa N, Mitsuishi Y, Ogasawara K, Tsuchiya H, Hiono T, Okamatsu M, Sakoda Y, Kida H, Ito M, Quynh Mai L, Kawaoka Y, Miyamoto H, Ishijima M, Igarashi M, Suzuki Y, Takada A. Protective efficacy of passive immunization with monoclonal antibodies in animal models of H5N1 highly pathogenic avian influenza virus infection. PLoS Pathog. 10:e1004192, 2014 (JUN 2014).
  7. Watanabe T, Zhong G, Russell CA, Nakajima N, Hatta M, Hanson A, McBride R, Burke DF, Takahashi K, Fukuyama S, Tomita Y, Maher A, Watanabe S, Imai M, Neumann G, Hasegawa H, Paulson JC, Smith DJ, Kawaoka Y. Circulating avian influenza viruses closely related to the 1918 virus have pandemic potential. Cell Host&Microbe 15:692-705, 2014 (JUN 11, 2014).
  8. Liu Z, Kato A, Shindo K, Noda T, Sagara H, Kawaoka Y, Arii J, Kawaguchi Y. Herpes simplex virus 1 UL47 interacts with viral nuclear egress factors UL31, UL34 and Us3, and regulates viral nuclear egress. J Virol 88:4657-4667, 2014.
  9. Li, W., Wen, C., Bai, H., Wang, X., Zhang, X., Huang, L., Yang, X., Iwamoto, A., and Liu, H. JNK signaling pathway is involved in piperlongumine-mediated apoptosis in human colorectal cancer HCT116 cells. Oncology Letters, in press, 2015.
  10. Lu, B., Wang, C., Zhang, J., Kuiper, R.P., Song, M., Zhang, X., MD, Song, S., van Kessel, Ad Geurts., Iwamoto, A., Wang, J., and Liu, H. Perivascular epithelioid cell tumor of gastrointestinal tract: case report and review of the literature. Medicine 94(3):e393, 2015 (JAN 2015)
  11. Gu, L., Kawana-Tachikawa, A., Shiino, T. , Nakamura, H., Koga, M., Kikuchi, T., Adachi, E., Koibuchi, T., Ishida, T. Gao, G.F., Matsushita, M., Sugiura, W., Iwamoto, A. and Hosoya, N. Development and customization of a color-coded microbeads-based assay for drug resistance in HIV-1 reverse transcriptase. PLoS ONE, 9(10):e109823, 2014 (OCT 14, 2014).
  12. Wang, Q., Qi, J., Yuan, Y., Xuan, Y., Han, P., Wan, Y., Ji, W., Li, Y., Wu, Y., Wang, J., Iwamoto, A., Woo, P.C.Y., Yuen, K-Y., Yan, J., Lu, G., and Gao, G.F. Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26. Cell Host&Microbe 16: 1-10, 2014 (SEP 10, 2014).
  13. Wang H, Li X, Nakane S, Liu S, Ishikawa H, Iwamoto A, Matsuda Z. Co-expression of foreign proteins tethered to HIV-1 envelope glycoprotein on the cell surface by introducing an intervening second membrane-spanning domain. PLoS ONE 9(5):e96790, 2014 (MAY 7, 2014).
  14. Han C, Kawana-Tachikawa A, Shimizu A, Zhu D, Nakamura H, Adachi E, Kikuchi T, Koga M, Koibuchi T, Gao GF, Sato Y, Yamagata A, Martin E, Fukai S, Brumme ZL, Iwamoto A. Switching and emergence of CTL epitopes in HIV-1 infection. Retrovirology 11:38,2014. doi:10.1186/1742-4690-11-38, 2014 (May 21, 2014).
  15. Ota Y, Hishima T, Mochizuki M, Kodama Y, Moritani S, Oyaizu N, Mine S, Ajisawa A, Tanuma J, Uehira T, Hagiwara S, Yajima K, Koizumi Y, Shirasaka T, Kojima Y, Nagai H, Yokomaku Y, Shiozawa Y, Koibuchi T, Iwamoto A, Oka S, Hasegawa H, Okada S, Katano H. Classification of AIDS- related lymphoma cases between 1987 and 2012 in Japan based on the WHO Classification of Lymphomas, fourth edition. Cancer Med. 3(1):143-53, 2014. doi: 10.1002/cam4.178.(FEB 2014).
  16. Li Y, Han Y, Xie J, Gu L, Li W, Wang H, Li W, Song X, Li Y, Routy JP, Ishida T, Iwamoto A and Li T. CRF01_AE subtype is associated with X4 tropism and fast HIV progression in Chinese patients infected through sexual transmission. AIDS, 28, 521-530, FEB 20 2014
  17. Kogai H, Kikuchi S, Obana T, Tsuboi Y, Maruyama T, Sakurai-Yageta M, Asamura H, Kanai Y, Murakami Y. Promoter methylation of the CADM1 and 4.1B genes occurs independently of the EGFR or the KRAS2 mutation in non-small cell lung cancer. Journal of Cancer Therapy, 6, 273-285, 2015 (MAR 2015).
  18. Sakurai-Yageta M, Maruyama T, Suzuki T, Ichikawa K, Murakami Y. Dynamic Regulation of a Cell Adhesion Protein Complex Including CADM1 by Combinatorial Analysis of FRAP with Exponential Curve-fitting. PLoS ONE, 10(3):e0116637,2015 (MAR 17 2015).
  19. Matsubara D, Murakami Y, Niki T. Immunohistochemical analysis of the expression of E-cadherin and ZEB1 in non-small cell lung cancer. Pathology International, 64(11):560-568, 2014. (doi: 10.1111/pin.12214) (NOV 2014).
  20. Ibrahim R, Matsubara D, Osman W, Morikawa T, Goto A, Morita S, Ishikawa S, Aburatani H, Takai D, Nakajima J, Fukayama M, Niki T, Murakami Y. Expression of PRMT5 in lung adenocarcinoma and its significance in epithelial-mesenchymal transition. Human Pathology 45, 1397-1405, 2014. (doi: 10.1016/j.humpath.2014.02.013.) (JUL 2014).
  21. Ebihara Y, Iwai M, Akashi K, Ito T, Omura G, Saito Y, Yoshida M, Ando M, Asakage T, Yamasoba T, Murakami Y. High incidence of null-type mutations of the TP53 gene in Japanese patients with head and neck squamous cell carcinoma. Journal of Cancer Therapy 5, 664-671, 2014. (doi.org/10.4236/jct.2014.57075) .(JUN 2014).
  22. Wang F, Akashi K, Murakami Y, Inoue Y, Furuta T, Yamada H, Ohtomo K, Kiryu S. Detection of lung tumors in mice using a 1-Tesla compact magnetic resonance imaging system. PLoS One 9, e94945, 2014. (doi: 10.1371/journal.pone.0094945. (APR 17, 2014).
  23. Cortez VS, Cervantes-Barragan L, Song C, Gilfillan S, McDonald KG, Edelson BT, Murakami Y, Newberry RD, Sibley LD, Colonna M. CRTAM controls residency of gut CD4+CD8+T cells in the steady state and maintenance of gut CD4 TH17 during parasitic infection. J Exp Med 211, 623-633, 2014. (DOI: 10.1084/jem.20130904.) (APR 7, 2014).
  24. Sato A, Suwanto A, Okabe M, Sato S, Nochi T, Imai T, Koyanagi N, Kunisawa J, Kawaguchi Y, Kiyono H. Vaginal memory T cells induced by intranasal vaccination are critical for protective T cell recruitment and prevention of genital HSV-2 disease. J Virol, 88(23), 13699-13708, 2014 (DEC 2014).
  25. Fujii H, Kato A, Mugitani M, Kashima Y, Oyama M, Kozuka-Hata H, Arii J, Kawaguchi Y. The UL12 Protein of Herpes Simplex Virus 1 Is Regulated by Tyrosine Phosphorylation. J Virol 88: 10624-10634, 2014 (SEP 2014).
  26. Maruzuru Y, Shindo K, Liu Z, Oyama M, Kozuka-Hata H, Arii J, Kato A, Kawaguchi Y. The Role of Herpes Simplex Virus 1 Immediate-Early Protein ICP22 in Viral Nuclear Egress. J Virol 88: 7445-7454, 2014 (JUL 2014).
  27. Kato A, Hirohata Y, Arii J, Kawaguchi Y. Phosphorylation of Herpes Simplex Virus 1 dUTPase Upregulated Viral dUTPase Activity to Compensate for Low Cellular dUTPase Activity for Efficient Viral Replication. J Virol 88: 7776-7785, 2014 (JUL 2014).
  28. Akiyama, T., Shiraishi, T., Qin, J., Konno, H., Akiya Ohashi, H., Miyamoto-Sato, E., Yanagawa, H., Yong, W., Shou, W. and Inoue, J. Mitochondria-nucleus shuttling FK506-binding protein 51 interacts with TRAF proteins and facilitates the RIG-I-like receptor-mediated expression of type I IFN. PLoS ONE 9(5):e95992, 2014. (doi:10.1371/journal.pone.0095992.) (MAY 1, 2014).
  29. Ohto U, Shibata T, Tanji H, Ishida H, Krayukhina E, Uchiyama S, Miyake K, Shimizu T. Structural basis of CpG and inhibitory DNA recognition by Toll-like receptor 9. Nature 2015. ( doi: 10.1038/nature14138.) (APR 30 2015).
  30. Li X, Saitoh SI, Shibata T, Tanimura N, Fukui R, Miyake K. Mucolipin 1 positively regulates TLR7 responses in dendritic cells by facilitating RNA transportation to lysosomes. Int Immunol 27:83-94, 2015. (doi: 10.1093/intimm/dxu086.) (FEB 2015).
  31. Kanno A, Tanimura N, Ishizaki M, Ohko K, Motoi Y, Onji M, Fukui R, Shimozato T, Yamamoto K, Shibata T, Sano S, Sugahara-Tobinai A, Takai T, Ohto U, Shimizu T, Saitoh S, Miyake K. Targeting cell surface TLR7 for therapeutic intervention in autoimmune diseases. Nat Commun 6, 2015. ( doi: 10.1038/ncomms7119.) (FEB 2015).
  32. Tanji H, Ohto U, Shibata T, Taoka M, Yamauchi Y, Isobe T, Miyake K, Shimizu T. Toll-like receptor 8 senses degradation products of single-stranded RNA. Nat Struct Mol Biol 22:109-15, 2015. ( doi: 10.1038/nsmb.2943.) (FEB 2015).
  33. Chan MP, Onji M, Fukui R, Kawane K, Shibata T, Saitoh SI, Ohto U, Shimizu T, Barber GN, Miyake K. DNase II-dependent DNA digestion is required for DNA sensing by TLR9. Nat Commun 6:5853, 2015. (doi: 10.1038/ncomms6853.) (JAN 2015).

2013

  1. Neumann G, Macken CA, Kawaoka Y. Identification of amino acid changes that may have been critical for the genesis of A(H7N9) influenza viruses. J Virol 88:4877-4896, 2014.
  2. Yamayoshi S, Yamada S, Fukuyama S, Murakami S, Zhao D, Uraki R, Watanabe T, Tomita Y, Macken C, Neumann G, Kawaoka Y. Virulence-affecting amino acid changes in the PA protein of H7N9 influenza A viruses. J Virol 88:3127-3134, 2014.
  3. Nakayama M, Shichinohe S, Itoh Y, Ishigaki H, Kitano M, Arikata M, Pham VL, Ishida H, Kitagawa N, Okamatsu M, Sakoda Y, Ichikawa T, Tsuchiya H, Nakamura S, Le QM, Ito M, Kawaoka Y, Kida H, Ogasawara K. Protection against H5N1 highly pathogenic avian and pandemic (H1N1) 2009 influenza virus infection in cynomolgus monkeys by an inactivated H5N1 whole particle vaccine. PLoS One 8:e82740, 2013.
  4. Wilker PR, Dinis JM, Starrett G, Imai M, Hatta M, Nelson CW, O窶僂onnor DH, Hughes AL, Neumann G, Kawaoka Y, Friedrich TC. Selection on haemagglutinin imposes a bottleneck during mammalian transmission of reassortant H5N1 influenza viruses. Nat Commun 4:2636, 2013.
  5. Imai M, Herfst S, Sorrell EM, Schrauwen EJ, Linster M, De Graaf M, Fouchier RA, Kawaoka Y. Transmission of influenza A/H5N1 viruses in mammals. Virus Res 178:15-20, 2013.
  6. Takahashi T, Song J, Suzuki T, Kawaoka Y. Mutations in NA that induced low pH-stability and enhanced the replication of pandemic (H1N1) 2009 influenza A virus at an early stage of the pandemic. PLoS One 8:e64439, 2013.
  7. Deng G, Tan D, Shi J, Cui P, Jiang Y, Liu L, Tian G, Kawaoka Y, Li C, Chen H. Complex reassortment of multiple subtypes of avian influenza viruses in domestic ducks at the Dongting Lake region of China. J Virol 87:9452-9462, 2013.
  8. Watanabe T, Kiso M, Fukuyama S, Nakajima N, Imai M, Yamada S, Murakami S, Yamayoshi S, Iwatsuki-Horimoto K, Sakoda Y, Takashita E, McBride R, Noda T, Hatta M, Imai H, Zhao D, Kishida N, Shirakura M, de Vries RP, Shichinohe S, Okamatsu M, Tamura T, Tomita Y, Fujimoto N, Goto K, Katsura H, Kawakami E, Ishikawa I, Watanabe S, Ito M, Sakai-Tagawa Y, Sugita Y, Uraki R, Yamaji R, Eisfeld AJ, Zhong G, Fan S, Ping J, Maher EA, Hanson A, Uchida Y, Saito T, Ozawa M, Neumann G, Kida H, Odagiri T, Paulson JC, Hasegawa H, Tashiro M, Kawaoka Y. Characterization of H7N9 influenza A viruses isolated from humans. Nature 501:551-555, 2013.
  9. Morita M, Kuba K, Ichikawa A, Nakayama M, Katahira J, Iwamoto R, Watanebe T, Sakabe S, Daidoji T, Nakamura S, Kadowaki A, Ohto T, Nakanishi H, Taguchi R, Nakaya T, Murakami M, Yoneda Y, Arai H, Kawaoka Y, Penninger JM, Arita M, Imai Y. The lipid mediator protectin d1 inhibits influenza virus replication and improves severe influenza. Cell 153:112-125, 2013.
  10. Kiso M, Takano R, Sakabe S, Katsura H, Shinya K, Uraki R, Watanabe S, Saito H, Toba M, Kohda N, Kawaoka Y. Protective efficacy of orally administered, heat-killed Lactobacillus pentosus b240 against influenza A virus. Sci Rep 3:1563, 2013.
  11. Kageyama T, Fujisaki S, Takashita E, Xu H, Yamada S, Uchida Y, Neumann G, Saito T, Kawaoka Y, Tashiro M. Genetic analysis of novel avian A(H7N9) influenza viruses isolated from patients in China, February to April 2013. Euro Surveill 18(15), 2013.
  12. Uraki R, Kiso M, Iwatsuki-Horimoto K, Fukuyama S, Takashita E, Ozawa M, Kawaoka Y. A novel bivalent vaccine based on a PB2-knockout influenza virus protects mice from pandemic H1N1 and highly pathogenic H5N1 virus challenges. J Virol 87:7874-7881, 2013.
  13. Ozawa M, Shimojima M, Goto H, Watanabe S, Hatta Y, Kiso M, Furuta Y, Horimoto T, Peters NR, Hoffmann FM, Kawaoka Y. A cell-based screening system for influenza A viral RNA transcription/replication inhibitors. Sci Rep 3:1106, 2013.
  14. Fan S, Macken CA, Li C, Ozawa M, Goto H, Iswahyudi, Nidom CA, Chen H, Neumann G, Kawaoka Y. Synergistic effect of the PDZ and the p85ホイ-binding domains of the NS1 protein in virulence of an avian H5N1 influenza A virus. J Virol 87:4861-4871, 2013.
  15. Watanabe T, Tisoncik-Go J, Tchitchek N, Watanabe S, Benecke AG, Katze MG, Kawaoka Y. 1918 HA and the viral RNA polymerase complex enhance viral pathogenicity, but only HA induces aberrant host responses in mice. J Virol 87:5239-5254, 2013.
  16. Uraki R, Kiso M, Shinya K, Goto H, Takano R, Iwatsuki-Horimoto K, Takahashi K, Daniels RS, Hungnes O, Watanabe T, Kawaoka Y. Virulence determinants of pandemic A(H1N1)2009 virus in a mouse model. J Virol 87:2226-2233, 2013.
  17. Muramoto Y, Noda T, Kawakami E, Akkina R, Kawaoka Y. Identification of novel influenza A virus proteins translated from PA mRNA. J Virol 87:2344-2362, 2013.
  18. Sakabe S, Takano R, Nagamura-Inoue T, Yamashita N, Nidom CA, Quynh Le MT, Iwatsuki-Horimoto K, Kawaoka Y. Differences in cytokine production in human macrophages and in virulence in mice are attributable to the acidic polymerase protein of highly pathogenic influenza A virus subtype H5N1. J Infect Dis 207: 262-271, 2013.
  19. Takano R, Kiso M, Igarashi M, Le QM, Sekijima M, Ito K, Takada A, Kawaoka Y. Molecular mechanisms underlying oseltamivir resistance mediated by an I117V substitution in the NA of H5N1 avian influenza viruses. J Infect Dis 207: 89-97, 2013.
  20. Shimizu A, Kawana-Tachikawa A, Yamagata A, Han C, Zhu D, Sato Y, Nakamura H, Koibuchi T, Carlson J, Martin E, Brumme CJ, Shi Y, Gao GF, Brumme ZL, Fukai S, Iwamoto A. Structure of TCR and antigen complexes at an immunodominant CTL epitope in HIV-1 infection. Sci Rep 3:3097, 2013. (doi:10.1038/srep03097.)
  21. Nishimura T, Kaneko S, Kawana-Tachikawa A, Tajima Y, Gotoh H, Zhu D, Nakayama K, Iriguchi S, Uemura Y, Shimizu T, Takayama N, Yamada D, Nishimura K, Ohtaka M, Watanabe N, Takahashi S, Iwamoto A, Koseki H, Nakanishi M, Eto K, Nakauchi H. Generation of rejuvenated antigen-specific T cells by pluripotency reprogramming and redifferentiation. Cell Stem Cell 12 (1): 114-126, 2013.
  22. Teeranaipong P, Hosoya N, Kawana-Tachikawa A, Fujii T, Koibuchi T, Nakamura H, Koga M, Kondo N, Gao GF, Hoshino H, Matsuda Z, Iwamoto A. Development of a rapid cell-fusion-based phenotypic HIV-1 tropism assay. J Int AIDS Soc 16:18723, 2013.
    http://www.jiasociety.org/index.php/jias/article/view/18723.
  23. Nomura S, Hosoya N, Brumme Z, Brockman M, Kikuchi T, Koga M, Nakamura H, Koibuchi T, Fujii T, Carlson J, Heckerman D, Kawana-Tachikawa A, Iwamoto A, Miura T. Significant reductions in gag-protease mediated HIV-1 replication capacity over the course of the epidemic in Japan. J Virol 87(3):1465-1476, 2013 Feb. (doi: 10.1128/JVI.02122-12. Epub 2012 Nov 14. PubMed PMID:23152532; PubMed Central PMCID: PMC3554148.)
  24. Atanasiu D, Saw WT, Gallagher JR, Hannah BP, Matsuda Z, Whitbeck JC, Cohen GH, Eisenberg RJ. A dual split protein-based fusion assay reveals that mutations to HSV glycoprotein gB alter the kinetics of cell-cell fusion induced by HSV entry glycoproteins. J Virol 2013 Aug 14. [Epub ahead of print]
  25. Li Y, Han Y, Xie J, Gu L, Li W, Wang H, Li W, Song X, Li Y, Routy JP, Ishida T, Iwamoto A, Li T. CRF01_AE subtype is associated with X4 tropism and fast HIV progression in Chinese patients infected through sexual transmission. AIDS, in press.
  26. Suzuki K, Hattori S, Marks K, Ahlenstiel C, Maeda Y, Ishida T, Millington M, Boyd M, Symonds G, Cooper DA, Okada S, Kelleher AD. Promoter targeting shRNA suppresses HIV-1 infection in vivo through transcriptional gene silencing. Mol Ther Nucleic Acids 2:e137, 2013.
  27. Ohsugi T, Ishida T, Shimasaki T, Okada S, Umezawa K. p53 dysfunction precedes the activation of nuclear factor-ホコB during disease progression in mice expressing Tax, a human T-cell leukemia virus type 1 oncoprotein. Carcinogenesis, in press.
  28. Nakano K, Ando T, Yamagishi M, Yokoyama K, Ishida T, Ohsugi T, Tanaka Y, Brighty DW, Watanabe T. Viral interference with host mRNA surveillance, the nonsense-mediated mRNA decay (NMD) pathway, through a new function of HTLV-1 Rex: implications for retroviral replication. Microbes Infect, in press.
  29. Yamamoto M, Taguchi Y, Ito-Kureha T, Semba K, Yamaguchi N, Inoue J. NF-ホコB non-cell-autonomously regulates cancer stem cell populations in the basal-like breast cancer subtype. Nat Commun 4:2299, 2013. (doi: 10.1038/ncomms3299.)
  30. Yamaguchi N, Oyama M, Kozuka-Hata H, Inoue J. Involvement of A20 in the molecular switch that activates the non-canonical NF-ホコB pathway. Sci Rep 3: 2568, 2013. (doi:10.1038/srep02568.)
  31. Tanimura N, Saitoh S, Ohto U, Akashi-Takamura S, Fujimoto Y, Fukase K, Shimizu T, Miyake K. The attenuated inflammation of MPL is due to the lack of CD14-dependent tight dimerization of TLR4/MD2 complex at the plasma membrane. Int Immunol, 2013. (doi:10.1093/intimm/dxt071.)
  32. Kayagaki N, Wong MT, Stowe IB, Ramani SR, Gonzalez LC, Akashi-Takamura S, Miyake K, Zhang J, Lee WP, Muszynski A, Forsberg LS, Carlson RW, Dixit VM. Noncanonical inflammasome activation by intracellular LPS independent of TLR4. Science 341(6151):1246-1249, 2013. (doi:10.1126/science.1240248.)
  33. Miyake K, Onji M. Endocytosis-free DNA sensing by cell surface TLR9 in neutrophils: Rapid defense with autoimmune risks. Eur J Immunol 43:2006-2009, 2013. (doi: 10.1002/eji.201343882.)
  34. Hiratsuka S, Ishibashi S, Tomita T, Watanabe A, Akashi-Takamura S, Murakami M, Kijima H, Miyake K, Aburatani H, Maru Y. Primary tumours modulate innate immune signalling to create pre-metastatic vascular hyperpermeability foci. Nat Commun 4:1853, 2013. (doi: 10.1038/ncomms2856.)
  35. Onji M, Kanno A, Saitoh S, Fukui R, Motoi Y, Shibata T, Matsumoto F, Lamichhane A, Sato S, Kiyono H, Yamamoto K, Miyake K. An essential role for the N-terminal fragment of Toll-like receptor 9 in DNA sensing. Nat Commun 4:1949, 2013. (doi:10.1038/ncomms2949.)
  36. Kawashima T, Kosaka A, Yan H, Guo Z, Uchiyama R, Fukui R, Kaneko D, Kumagai Y, You DJ, Carreras J, Uematsu S, Jang MH, Takeuchi O, Kaisho T, Akira S, Miyake K, Tsutsui H, Saito T, Nishimura I, Tsuji NM. Double-stranded RNA of intestinal commensal but not pathogenic bacteria triggers production of protective interferon-ホイ. Immunity 38(6):1187-1197, 2013. (doi: 10.1016/j.immuni.2013.02.024.)
  37. Tanji H, Ohto U, Shibata T, Miyake K, Shimizu T. Structural reorganization of the Toll-like receptor 8 dimer induced by agonistic ligands. Science 339:1426-1429, 2013. (doi: 10.1126/science.1229159.)
  38. Arai S, Maehara N, Iwamura Y, Honda SI, Nakashima K, Kai T, Ogishi M, Morita K, Kurokawa J, Mori M, Motoi Y, Miyake K, Matsuhashi N, Yamamura KI, Ohara O, Shibuya A, Wakeland EK, Li QZ, Miyazaki T. Obesity-associated autoantibody production requires AIM to retain the immunoglobulin M immune complex on follicular dendritic cells. Cell Rep 3(4):1187-1198, 2013. (doi: 10.1016/j.celrep.2013.03.006.)
  39. Tsukamoto H, Fukudome K, Takao S, Tsuneyoshi N, Ohta S, Nagai Y, Ihara H, Miyake K, Ikeda Y, Kimoto M. Reduced surface expression of TLR4 by a V254I point mutation accounts for the low lipopolysaccharide responder phenotype of BALB/c B Cells. J Immunol 190:195-204, 2013.
  40. Kanno A, Yamamoto C, Onji M, Fukui R, Saitoh SI, Motoi Y, Shibata T, Matsumoto F, Muta T, Miyake K. Essential role for Toll-like receptor 7 (TLR7)-unique cysteines in intramolecular disulfide bond, proteolytic cleavage, and RNA-sensing. Int Immunol, in press.
  41. Kondo Y, Ikeda K, Tokuda N, Nishitani C, Akashi-Takamura S, Ito Y, Uchikawa M, Kuroki Y, Taguchi R, Miyake K, Zhang Q, Furukawa K, Furukawa K. TLR4-MD-2 complex is negatively regulated by an endogenous ligand, globotetraosylceramide. Proc Natl Acad Sci U S A, in press.
  42. Yamakawa N, Ohto U, Akashi-Takamura S, Takahashi K, Saitoh SI, Tanimura N, Suganami T, Ogawa Y, Shibata T, Shimizu T, Miyake K. Human TLR4 polymorphism D299G/T399I alters TLR4/MD-2 conformation and response to a weak ligand monophosphoryl lipid A. Int Immunol, in press.
  43. Ito T, Sakurai-Yageta M, Goto A, Murakami Y. Genomic and transcriptional alterations of cholangiocarcinoma. Journal of Hepato-Biliary-Pancreatic Sciences, in press.
  44. Murakami S, Sakurai-Yageta M, Maruyama T, Murakami Y. Intercellular adhesion of CADM1 activates PI3K by forming a complex with MAGuK-family proteins MPP3 and Dlg. PLoS One 9:e82894, 2014. (DOI: 10.1371/journal.pone.0082894.)
  45. Mimae T, Hagiyama M, Inoue T, Yoneshige A, Kato T, Okada M, Murakami Y, Ito A. Increased ectodomain shedding of lung-epithelial cell adhesion molecule 1 as a cause of increased alveolar cell apoptosis in emphysema. Thorax 67(3):223-231, 2014. (DOI: 10.1136/thoraxjnl-2013-203867.)
  46. Matsubara D, Kishaba Y, Ishikawa S, Sakatani T, Oguni S, Tamura T, Hoshino H, Sugiyama Y, Endo S, Murakami Y, Aburatani H, Fukayama M, Niki T. Lung cancer with loss of BRG1/BRM, shows epithelial mesenchymal transition phenotype and distinct histologic and genetic features. Cancer Sci 104: 266-273, 2013. (doi: 10.1111/cas.12065.)
  47. Imamura K, Imamachi N, Akizuki G, Kumakura M, Kawaguchi A, Nagata K, Kato A, Kawaguchi Y, Sato H, Yoneda M, Kai C, Yada T, Suzuki Y, Yamada T, Ozawa T, Kaneki K, Inoue T, Kobayashi M, Kodama T, Wada Y, Sekimizu K, Akimitsu N. Long noncoding RNA NEAT1-dependent SFPQ relocation from promoter region to paraspeckle mediates IL8 expression upon immune stimuli. Mol Cell 53:393-406, 2014.
  48. Liu Z, Kato A, Shindo K, Noda T, Sagara H, Kawaoka Y, Arii J, Kawaguchi Y. Herpes simplex virus 1 UL47 interacts with viral nuclear egress factors UL31, UL34 and Us3, and regulates viral nuclear egress. J Virol 88:4657-4667, 2014.
  49. Koyanagi N, Imai T, Arii J, Kato A, Kawaguchi Y. Roles of herpes simplex virus 1 Us3 in viral neuroinvasiveness. Microbiol Immunol 58:31-37, 2014.
  50. Fujii H, Mugitani M, Koyanagi N, Liu Z, Tsuda S, Arii J, Kato A, Kawaguchi Y. Role of the nuclease activities encoded by herpes simplex virus 1 UL12 in viral replication and neurovirulence. J Virol 88:2359-2364, 2014.
  51. Kato A, Shindo K, Maruzuru Y, Kawaguchi Y. Phosphorylation of a herpes simplex virus 1 dUTPase by a viral protein kinase Us3 dictates viral pathogenicity in the central nervous system but not at the periphery. J Virol 88:2775-2785, 2014.
  52. Kato A, Tsuda S, Liu Z, Kozuka-Hata H, Oyama M, Kawaguchi Y. Herpes simplex virus 1 protein kinase Us3 phosphorylates viral dUTPase and regulates its catalytic activity in infected cells. J Virol 88:655-666, 2014.
  53. Imai T, Koyanagi N, Ogawa R, Shindo K, Suenaga T, Sato A, Arii J, Kato A, Kiyono H, Arase H, and Kawaguchi Y. Us3 kinase encoded by herpes simplex virus 1 mediates downregulation of cell surface major histocompatibility complex class I and evasion of CD8+ T cells. PLoS One 8:e72050, 2013.
  54. Maruzuru Y, Fujii H, Oyama M, Kozuka-Hata H, Kato A and Kawaguchi Y. Roles of p53 in herpes simplex virus 1 replication. J Virol 87:9323-9332, 2013.
  55. Kawaguchi Y. Us3, a multi-functional protein kinase encoded by herpes simplex virus 1: how does it function in vivo? Cornea 32:S22-S27, 2013.
  56. Sage VL, Jung M, Alter JD, Wills EG, Johnston SM, Kawaguchi Y, Baines JD and Banfield BW. The herpes simplex virus type 2 UL21 protein is essential for virus propagation. J Virol 87:5904-5915, 2013.

2012

  1. Takahashi T, Nidom CA, Quynh Le MT, Suzuki T, Kawaoka Y. Amino acid determinants conferring stable sialidase activity at low pH for H5N1 influenza A virus neuraminidase. FEBS Open Bio 2:261-265, 2012.
  2. Shoemaker JE, Fukuyama S, Eisfeld AJ, Muramoto Y, Watanabe S, Watanabe T, Matsuoka Y, Kitano H, Kawaoka Y. Integrated network analysis reveals a novel role for the cell cycle in 2009 pandemic influenza virus-induced inflammation in macaque lungs. BMC Syst Biol 6:117, 2012.
  3. Das SC, Hatta M, Wilker PR, Myc A, Hamouda T, Neumann G, Baker JR Jr, Kawaoka Y. Nanoemulsion W(80)5EC improves immune responses upon intranasal delivery of an inactivated pandemic H1N1 influenza vaccine. Vaccine 30:6871-6877, 2012.
  4. Imai M, Watanabe S, Kawaoka Y. The cytoplasmic tail domain of influenza B virus hemagglutinin is important for its incorporation into virions but is not essential for virus replication in cell culture in the presence of compensatory mutations. J Virol 86:11633-11644, 2012.
  5. Shimojima M, Kawaoka Y. Cell surface molecules involved in infection mediated by lymphocytic choriomeningitis virus gycoprotein. J Vet Med Sci 74:1363-1366, 2012.
  6. Shimojima M, Ströher U, Ebihara H, Feldmann H, Kawaoka Y. Identification of cell surface molecules involved in dystroglycan-independent Lassa virus cell entry. J Virol 86: 2067-2078, 2012.
  7. Victor ST, Watanabe S, Katsura H, Ozawa M, Kawaoka Y. A replication-incompetent PB2-knockout influenza A virus vaccine vector. J Virol 86: 4123-4128, 2012.
  8. Nidom CA, Yamada S, Nidom RV, Rahmawati K, Alamudi MY, Kholik, Indrasari S, Hayati RS, Iwatsuki Horimoto K, Kawaoka Y. Genetic characterization of H5N1 influenza viruses isolated from chickens in Indonesia in 2010. Virus Genes 44: 459-465, 2012.
  9. Shinya K, Gao Y, Cilloniz C, Suzuki Y, Fujie M, Deng G, Zhu Q, Fan S, Makino A, Muramoto Y, Fukuyama S, Tamura D, Noda T, Eisfeld AJ, Katze MG, Chen H, Kawaoka Y. Integrated clinical, pathologic, virologic, and transcriptomic analysis of H5N1 influenza virus-induced viral pneumonia in the rhesus macaque. J Virol 86: 6055-6066, 2012.
  10. Kikuchi T, Iwatsuki-Horimoto K, Adachi E, Koga M, Nakamura H, Hosoya N, Kawana-Tachikawa A, Koibuchi T, Miura T, Fujii T, Kawaoka Y, Iwamoto A. Improved neutralizing antibody response in the second season after a single dose of pandemic (H1N1) 2009 influenza vaccine in HIV-1-positive adults. Vaccine 30: 3819-3823, 2012.
  11. Watanabe T, Imai M, Watanabe S, Shinya K, Hatta M, Li C, Neumann G, Ozawa M, Hanson A, Zhong G, Fukuyama S, Kawakami E, Simmons HA, Schenkman D, Brunner K, Capuano SV 3rd, Weinfurter JT, Kilander A, Dudman SG, Suresh M, Hungnes O, Friedrich TC, Kawaoka Y. Characterization in vitro and in vivo of pandemic (H1N1) 2009 viruses isolated from patients. J Virol 86: 9361-9368, 2012.
  12. Zhang Y, Zhang Q, Gao Y, He X, Kong H, Jiang Y, Guan Y, Xia X, Shu Y, Kawaoka Y, Bu Z, Chen H. Key molecular factors in HA and PB2 contribute to the efficient transmission of the 2009 H1N1 pandemic influenza virus. J Virol 86: 9666-9674, 2012.
  13. Inagaki A, Goto H, Kakugawa S, Ozawa M, Kawaoka Y. Competitive incorporation of homologous gene segments of influenza A virus into virions. J Virol 86: 10200-10202, 2012.
  14. Okame M, Adachi E, Sato H, Shimizu S, Kikuchi T, Miyazaki N, Koga M, Nakamura H, Suzuki M, Oyaizu N, Fujii T, Iwamoto A, Koibuchi T. Shigella sonnei outbreak among men who have sex with men (MSM) in Tokyo. Jpn J Infect Dis 65: 277-278, 2012.
  15. Adachi E, Koibuchi T, Imai K, Kikuchi T, Koga M, Nakamura H, Miura T, Iwamoto A, Fujii T. Favourable outcome of progressive multifocal leukoencephalopathy with mefloquine treatment in combination with antiretroviral therapy in an HIV-infected patient. International Journal of STD & AIDS 23:603-605, 2012.
  16. Ishikawa H, Meng F, Kondo N, Iwamoto A, Matsuda Z. Generation of a dual-functional split-reporter protein for monitoring membrane fusion using self-associating split GFP. Protein Engineering, Design & Selection (2012)縲€doi: 10.1093/protein/gzs051, first published online: August 30, 2012.
  17. Saito M, Kato Y, Ito E, Fujimoto J, Ishikawa K, Doi A, Kumazawa K, Matsui A, Takebe S, Ishida T, Azuma S, Mochizuki H, Kawamura Y, Yanagisawa Y, Honma R, Imai J, Ohbayashi H, Goshima N, Semba K, Watanabe S. Expression screening of 17q12-21 amplicon reveals GRB7 as an ERBB2-dependent oncogene. FEBS Lett 12;586(12): 1708-1714, 2012.
  18. Kobayashi-Ishihara M, Yamagishi M, Hara T, Matsuda Y, Takahashi R, Miyake A, Nakano K, Yamochi T, Ishida T, Watanabe T. HIV-1-encoded antisense RNA suppresses viral replication for a prolonged period. Retrovirology 9:38, 2012.
  19. Taguchi Y, Kiga Y, Gohda J, Inoue J. Identification and characterization縲€of anti-osteoclastogenic peptides derived from the cytoplasmic tail of RANK. J Bone Miner Metab 30: 543-553, 2012.
  20. Shibata Y, Oyama M, Kozuka-Hata H, Han X, Tanaka Y, Gohda J, Inoue J. p47 negatively regulates IKK activation by inducing the lysosomal degradation of polyubiquitinated NEMO. Nat Commun 3:1061 doi:10.1038/ncomms2068, 2012.
  21. Oshima D, Inoue J, Ichikawa K. Roles of spatial parameters on the oscillation of nuclear NF-ホコB: computer simulations of a 3D spherical cell. PLoS ONE 7(10): e46911, 2012.
  22. Yamaguchi N, Yokota M, Taguchi Y, Gohda J, Inoue J. cIAP1/2 negatively regulate RANKL-induced osteoclastogenesis through the inhibition of NFATc1 expression. Genes Cells 17: 971-981, 2012.
  23. Doronin K, Flatt JW, Di Paolo NC, Khare R, Kalyuzhniy O, Acchione M, Sumida JP, Ohto U, Shimizu T, Akashi-Takamura S, Miyake K, Macdonald JW, Bammler TK, Beyer RP, Farin FM, Stewart PL, Shayakhmetov DM. Coagulation Factor X Activates Innate Immunity to Human Species C Adenovirus. Science 338(6108): 795-798, 2012.
  24. Ohto U, Yamakawa N, Akashi-Takamura S, Miyake K, Shimizu T.縲€ Structural analyses of human Toll-like receptor 4 polymorphisms D299G and T399I. J Biol Chem, 2012 (Epub ahead of print).
  25. Nagai Y, Yanagibashi T, Watanabe Y, Ikutani M, Kariyone A, Ohta S, Hirai Y, Kimoto M, Miyake K, Takatsu K. The RP105/MD-1 complex is indispensable for TLR4/MD-2-dependent proliferation and IgM-secreting plasma cell differentiation of marginal zone B cells. Int Immunol 24: 389-400, 2012.
  26. Watanabe Y, Nakamura T, Ishikawa S, Fujisaka S, Usui I, Tsuneyama K, Ichihara Y, Wada T, Hirata Y, Suganami T, Izaki H, Akira S, Miyake K, Kanayama HO, Shimabukuro M, Sata M, Sasaoka T, Ogawa Y, Tobe K, Takatsu K, Nagai Y. The radioprotective 105/MD-1 complex contributes to diet-induced obesity and adipose tissue inflammation. Diabetes 61: 1199-1209, 2012.
  27. Honda H, Nagai Y, Matsunaga T, Saitoh SI, Akashi-Takamura S, Hayashi H, Fujii I, Miyake K, Muraguchi A, Takatsu K. Cyrrhizin and isoliquiritigenin suppress the LPS sensor Toll-like receptor 4/MD-2 complex signaling in a different manner. J Leukoc Biol 91: 967-976, 2012.
  28. Eguchi K, Manabe I, Oishi-Tanaka Y, Ohsugi M, Kono N, Ogata F, Yagi N, Ohto U, Kimoto M, Miyake K, Tobe K, Arai H, Kadowaki T, Nagai R. Saturated fatty acid and TLR signaling link ホイ cell dysfunction and islet inflammation. Cell Metab 15: 518-533, 2012.
  29. Ohto U, Fukase K, Miyake K, Shimizu T. Structural basis of species-specific endotoxin sensing by innate immune receptor TLR4/MD-2. Proc Natl Acad Sci USA 109: 7421-7426, 2012.
  30. Shichita T, Hasegawa E, Kimura A, Morita R, Sakaguchi R, Takada I, Sekiya T, Ooboshi H, Kitazono T, Yanagawa T, Ishii T, Takahashi H, Mori S, Nishibori M, Kuroda K, Akira S, Miyake K, Yoshimura A. Peroxiredoxin family proteins are key initiators of post-ischemic inflammation in the brain. Nat Med 18: 911-917, 2012.
  31. Fukui R, Miyake K. Controlling systems of nucleic acid sensing-TLRs restrict homeostatic inflammation. Exp Cell Res 318: 1461-1466, 2012.
  32. Shibata T, Takemura N, Motoi Y, Goto Y, Karuppuchamy T, Izawa K, Li X, Akashi-Takamura S, Tanimura N, Kunisawa J, Kiyono H, Akira S, Kitamura T, Kitaura J, Uematsu S, Miyake K. PRAT4A-dependent expression of cell surface TLR5 on neutrophils, classical monocytes and dendritic cells. Int Immunol (2012) Jul 25 (Epub ahead of print).
  33. Matsubara D, Kanai Y, Ishikawa S, Ohara S, Yoshimoto T, Sakatani T, Oguni S, Tamura T, Kataoka H, Endo S, Murakami Y, Aburatani H, Fukayama M, Niki T. Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad. J Thorac Oncol 7:1872-1876, 2012. (DOI: 10.1097/JTO.0b013e3182721ed1.)
  34. Ishimura M, Sakurai-Yageta M, Maruyama T, Ando T, Fukayama M, Goto A, Murakami Y. Involvement of miR-214 and miR-375 in malignant features of non-small-cell lung cancer by down-regulating CADM1. J Cancer Therapy 3:379-387, 2012. (DOI: 10.4236/jct.2012.324050.・・/li>
  35. Ito A, Mimae T, Yamamoto Y-S-Z, Hagiyama M, Nakanishi J, Ito M, Hosokawa Y, Okada M, Murakami Y, Kondo T. Novel application for pseudopodia proteomics using excimer laser ablation and two-dimensional difference gel electrophoresis. Lab Invest 92:1374-1385, 2012. (DOI: 10.1038/labinvest.2012.98.)
  36. Nakata H, Wakayama T, Adthapanyawanich K, Nishiuchi T, Murakami Y, Takai Y, Iseki S. Compensatory upregulation of myelin protein zero-like 2 expression in spermatogenic cells in cell adhesion molecule-1-deficient mice. Acta Histochem Cytochem 45:47-56, 2012.
  37. Kikuchi S, Iwai M, Sakurai-Yageta M, Tsuboi Y, Ito T, Masuda T, Tsuda H, Kanai Y, Onizuka M, Sato Y, Murakami Y. Expression of a splicing variant of the CADM1 specific to small cell lung cancer. Cancer Science 103: 1051-1057, 2012.
  38. Mimae T, Okada M, Hagiyama M, Miyata Y, Tsutani Y, Inoue T, Murakami Y, Ito A. Notch2 and Six1 are up-regulated during progression of early-stage lung adenocarcinoma and define its unfavorable subset at advanced stages. Clinical Cancer Research 18: 945-948, 2012.
  39. Nagara Y, Hagiyama M, Hatano, N, Futai, E, Suo S, Takaoka Y, Murakami Y, Ishiura S, Ito A. Tumor suppressor cell adhesion molecule 1 (CADM1) is cleaved by A disintegrin and metalloprotease 10 (ADAM10) and subsequently cleaved by gamma-secretase complex. Biochem Biophys Res Commun 417: 462-467, 2012.
  40. Takahashi Y, Iwai M, Kawai T, Arakawa A, Ito T, Sakurai-Yageta M, Ito A, Goto A, Saito M, Kasumi F, Murakami Y. Aberrant expression of tumor suppressors, CADM1 and 4.1B, in invasive lesions of primary breast cancer. Breast Cancer 19: 242-252, 2012.
  41. Nagata M, Sakurai-Yageta M, Yamada D, Goto A, Ito A, Fukuhara H, Kume H, Morikawa T, Fukayama M, Homma Y, Murakami Y. Aberrations of a cell adhesion molecule CADM4 in renal clear cell carcinoma. Int J Cancer 130: 1329-1337, 2012.
  42. Tanaka M, Kato A, Satoh Y, Ide T, Sagou K, Kimura K, Hasegawa H, Kawaguchi Y. Herpes simplex virus 1 VP22 regulates translocation of multiple viral and cellular proteins and promotes neurovirulence. J Virol 86: 5264-5277, 2012.

2011

  1. Das SC, Watanabe S, Hatta M, Noda T, Neumann G, Ozawa M, Kawaoka Y. The arginine residues at positions 76-78 of influenza A virus matrix protein M1 play an important role in viral replication. J Virol (2011) Nov 16 (Epub ahead of print).
  2. Murakami S, Horimoto T, Ito M, Takano R, Katsura H, Shimojima M, Kawaoka Y. Enhanced growth of influenza vaccine seed viruses in Vero cells mediated by broadening the optimal pH range for virus membrane fusion. J Virol (2011) Nov 16 (Epub ahead of print).
  3. Yamada S, Shinya K, Takada A, Ito T, Suzuki T, Suzuki Y, Le QM, Ebina M, Kasai N, Kida H, Horimoto T, Rivailler P, Chen LM, Donis RO, Kawaoka Y. Adaptation of a duck influenza A virus in quail. J Virol (2011) Nov 16 (Epub ahead of print).
  4. Ginting TE, Shinya K, Kyan Y, Makino A, Matsumoto N, Kaneda S, Kawaoka Y. Amino acid changes in hemagglutinin contribute to the replication of oseltamivir-resistant H1N1 influenza viruses. J Virol 86:121-127, (2012) Epub 2011 October 19.
  5. Watanabe T, Shinya K, Watanabe S, Imai M, Hatta M, Li C, Wolter BF, Neumann G, Hanson A, Ozawa M, Yamada S, Imai H, Sakabe S, Takano R, Iwatsuki-Horimoto K, Kiso M, Ito M, Fukuyama S, Kawakami E, Gorai T, Simmons HA, Schenkman D, Brunner K, Capuano SV 3rd, Weinfurter JT, Nishio W, Maniwa Y, Igarashi T, Makino A, Travanty EA, Wang J, Kilander A, Dudman SG, Suresh M, Mason RJ, Hungnes O, Friedrich TC, Kawaoka Y. Avian-type receptor-binding ability can increase influenza virus pathogenicity in macaques. J Virol 85:13195-13203, 2011.
  6. Octaviani CP, Goto H, Kawaoka Y. Reassortment between seasonal H1N1 and pandemic (H1N1) 2009 influenza viruses is restricted by limited compatibility among polymerase subunits. J Virol 85:8449-8452, 2011.
  7. Horimoto T, Maeda K, Murakami S, Kiso M, Iwatsuki-Horimoto K, Sashika M, Ito T, Suzuki K, Yokoyama M, Kawaoka Y. Highly pathogenic avian influenza virus infection in feral raccoons, Japan. Emerging Infectious Diseases 17:714-717, 2011.
  8. Shimizu K, Li C, Muramoto Y, Yamada S, Arikawa J, Chen H, Kawaoka Y. The NP and M segments of H5N1 influenza viruses are responsible for dominance in embryonated eggs. J Gen Virol 92:1645-1649, 2011.
  9. Kondo N, Miyauchi K, Matsuda Z. Monitoring viral-mediated membrane fusion using fluorescent reporter methods. Curr Protoc Cell Biol, Chapter 26: Unit 26.9, 2011.
  10. Shinya K, Makino A, Tanaka H, Hatta M, Watanabe T, Le MQ, Imai H, Kawaoka Y. Systemic dissemination of H5N1 influenza A viruses in ferrets and hamsters after direct intragastric inoculation. J Virol 85:4673-4678, 2011.
  11. Shinya K, Makino A, Hatta M, Watanabe S, Kim JH, Hatta Y, Gao P, Ozawa M, Le QM, Kawaoka Y. Subclinical brain injury caused by H5N1 influenza virus infection. J Virol 85:5202-5207, 2011.
  12. Shinya K, Okamura T, Sueta S, Kasai N, Tanaka M, Ginting TE, Makino A, Eisfeld AJ, Kawaoka Y. Toll-like receptor pre-stimulation protects mice against lethal infection with highly pathogenic influenza viruses. Virol J 8:97, 2011.
  13. Sakabe S, Iwatsuki-Horimoto K, Takano R, Nidom CA, Le MT, Nagamura-Inoue T, Horimoto T, Yamashita N, Kawaoka Y. Cytokine production by primary human macrophages infected with highly pathogenic H5N1 or pandemic H1N1 2009 influenza viruses. J Gen Virol 92:1428-1434, 2011.
  14. Kiso M, Ozawa M, Le MT, Imai H, Takahashi K, Kakugawa S, Noda T, Horimoto T, Kawaoka Y. Effect of an asparagine-to-serine mutation at position 294 in neuraminidase on the pathogenicity of highly pathogenic H5N1 influenza A virus. J Virol 85:4667-4672, 2011.
  15. Iwatsuki-Horimoto K, Horimoto T, Tamura D, Kiso M, Kawakami E, Hatakeyama S, Ebihara Y, Koibuchi T, Fujii T, Takahashi K, Shimojima M, Sakai-Tagawa Y, Ito M, Sakabe S, Iwasa A, Takahashi K, Ishii T, Gorai T, Tsuji K, Iwamoto A, Kawaoka Y. Sero-prevalence of pandemic (H1N1) 2009 Influenza A Virus among schoolchildren and their parents in Tokyo, Japan. Clin Vaccine Immunol 18:860-866, 2011.
  16. Ozawa M, Basnet S, Burley LM, Neumann G, Hatta M, Kawaoka Y. Impact of amino acid mutations in PB2, PB1-F2, and NS1 on the replication and pathogenicity of pandemic (H1N1) 2009 influenza viruses. J Virol 85:4596-5601, 2011.
  17. Tamura D, Sugaya N, Ozawa M, Takano R, Ichikawa M, Yamazaki M, Kawakami C, Shimizu H, Uehara R, Kiso M, Kawakami E, Mitamura K, Kawaoka Y. Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors. Clin Infect Dis 52:432-7, 2011.
  18. Shinya K, Ito M, Makino A, Tanaka M, Miyake K, Eisfeld AJ, Kawaoka Y. The TLR4-TRIF Pathway Protects against H5N1 Influenza Virus Infection. J Virol 86:19-24, (2012) Epub 2011 Oct 26.
  19. Hatakeyama S, Iwatsuki-Horimoto K, Okamoto K, Nukui Y, Yata N, Fujita A, Inaba S, Yotsuyanagi H, Kawaoka Y. Unadjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected adults. Vaccine 29(49):9224-9228, 2011.
  20. Ozawa M, Victor ST, Taft AS, Yamada S, Li C, Hatta M, Das SC, Takashita E, Kakugawa S, Maher EA, Neumann G, Kawaoka Y. Replication-incompetent influenza A viruses that stably express a foreign gene. J Gen Virol 92 (Pt 12):2879-2888, 2011.
  21. Sakabe S, Ozawa M, Takano R, Iwastuki-Horimoto K, Kawaoka Y. Mutations in PA, NP, and HA of a pandemic (H1N1) 2009 influenza virus contribute to its adaptation to mice. Virus Res 158 (1-2):124-129, 2011.
  22. Liu J, Chen P, Jiang Y, Wu L, Zeng X, Tian G, Ge J, Kawaoka Y, Bu Z, Chen H. A duck enteritis virus-vectored bivalent live vaccine provides fast and complete protection against H5N1 avian influenza virus infection in ducks. J Virol 85 (21):10989-10998, 2011.
  23. Yamaoka M, Palilingan JF, Wibisono J, Yudhawati R, Nidom RV, Alamudi MY, Ginting TE, Makino A, Nidom CA, Shinya K, Kawaoka Y. Virological surveillance of human influenza in Indonesia, October 2008-March 2010. Microbiol Immunol 55:514-517, 2011.
  24. Poetranto ED, Yamaoka M, Nastri AM, Krisna LA, Rahman MH, Wulandari L, Yudhawati R, Ginting TE, Makino A, Shinya K, Kawaoka Y. An H5N1 highly pathogenic avian influenza virus isolated from a local tree sparrow in Indonesia. Microbiol Immunol 55:666-672, 2011.
  25. Nakayama K, Nakamura H, Koga M, Koibuchi T, Fujii T, Miura T, Iwamoto A, Kawana-Tachikawa A. Imbalanced Production of Cytokines by T Cells Associates with the Activation/Exhaustion Status of Memory T Cells in Chronic HIV Type 1 Infection. AIDS Res Hum Retroviruses (2011) Sep 23 (Epub ahead of print).
  26. Shi Y, Qi J, Iwamoto A, Gao G.F. Plasticity of human CD8ホアホア binding to peptide-HLA-A*2402. Mol Immunol 48:2198-2202, (2011) Epub 2011Jun 6.
  27. Adachi E, Koibuchi T, Okame M, Sato H, Imai K, Shimizu S, Tsurita G, Oyaizu N, Iwamoto A, Fujii T. A case of secondary syphilis presenting with unusual complications: syphilitic proctitis, gastritis and hepatitis. J Clin Microbiol 49:4394-4396, (2011) Epub 2011 Oct 12.
  28. Imai K, Koibuchi T, Kumagai T, Maeda T, Osada Y, Ohta N, Koga M, Nakamura H, Miura T, Iwamoto A, Fujii T. Cerebral schistosomiasis due to Schistosoma haematobium confirmed by PCR analysis of brain specimen. J Clin Microbiol 49:3703-3706, (2011) Epub 2011 Aug 17.
  29. Long Y, Meng F, Kondo N, Iwamoto A, Matsuda Z. Conserved arginine residue in the membrane-spanning domain of HIV-1 gp41 is required for efficient membrane fusion. Protein Cell 2:369-376, 2011.
  30. Ahlenstiel C, Lim H, Cooper DA, Ishida T, Kelleher, AD, Suzuki, K. Direct evidence of nuclear Argonaute distribution during transcriptional silencing links the actin cytoskeleton to nuclear RNAi machinery in human cells. Nuc Acid Res, published on line: November 7, 2011. doi:10.1093/nar/gkr891.
  31. Suzuki K, Ishida T, Yamagishi M, Ahlenstiel C, Swaminathan S, Marks K, Murray D, McCartney EM, Beard MR, Alexander M, Purcell DF, Cooper DA, Watanabe T, Kelleher AD. Transcriptional gene silencing of HIV-1 through promoter targeted RNA is highly specific. RNA Biology 8:1035-46, 2011.
  32. Ashida H, Ogawa M, Kim M, Mimuro H, Sasakawa C. Bacteria and host interactions in the gut epithelial barrier. Nat Chem Biol 8:36-45, (2012) Epub 2011 Dec 15.
  33. Ashida H, Mimuro H, Ogawa M, Kobayashi T, Sanada T, Kim M, Sasakawa C. Host-pathogen interactions: Cell death and infection: A double-edged sword for host and pathogen survival. J Cell Biol 195:931-942, (2011) Epub 2011 Nov 28.
  34. Ogawa M, Sasakawa C. The role of Tecpr1 in selective autophagy as a cargo receptor. Autophagy 7:1389-1391, (2011) Epub 2011 Nov 1.
  35. Ashida H, Ogawa M, Mimuro H, Kobayashi T, Sanada T, Sasakawa C. Shigella are versatile mucosal pathogens that circumvent the host innate immune system. Curr Opin Immunol 23:448-455, (2011) Epub 2011 Jul 15.
  36. Suzuki M, Kiga K, Kersulyte D, Cok J, Hooper CC, Mimuro H, Sanada T, Suzuki S, Oyama M, Kozuka-Hata H, Kamiya S, Zou QM, Gilman RH, Berg DE, Sasakawa C. Attenuated CagA oncoprotein in Helicobacter pylori from Amerindians in Peruvian Amazon. J Biol Chem 286:29964-29972, (2011) Epub 2011 Jul 8.
  37. Ogawa M, Mimuro H, Yoshikawa Y, Ashida H, Sasakawa C. Manipulation of autophagy by bacteria for their own benefit. Microbiol Immunol 55:459-471, 2011.
  38. Ishijima N, Suzuki M, Ashida H, Ichikawa Y, Kanegae Y, Saito I, Boren T, Haas R, Sasakawa C, Mimuro H. BabA-mediated adherence is a potentiator of the Helicobacter pylori type IV secretion system activity. J Biol Chem 286:25256-25264, (2011) Epub 2011 May 19.
  39. Ogawa M, Yoshikawa Y, Kobayashi T, Mimuro H, Fukumatsu M, Kiga K, Piao Z, Ashida H, Yoshida M, Kakuta S, Koyama T, Goto Y, Nagatake T, Nagai S, Kiyono H, Kawalec M, Reichhart JM, Sasakawa C. A Tecpr1-dependent selective autophagy pathway targets bacterial pathogens. Cell Host Microbe 9:376-389, May 2011.
  40. Ogawa M, Yoshikawa Y, Mimuro H, Hain T, Chakraborty T, Sasakawa C. Autophagy targeting of Listeria monocytogenes and the bacterial countermeasure. Autophagy 7:310-4, Mar (2011).
  41. Kato A, Liu Z, Minowa A, Imai T, Tanaka M, Sugimoto K, Nishiyama Y, Arii J, Kawaguchi Y. Herpes Simplex Virus 1 Protein Kinase Us3 and Major Tegument Protein UL47 Reciprocally Regulate Their Subcellular Localization in Infected Cells. J Virol 85:9599-9613, (2011) Epub 2011 Jul 6.
  42. Imai T, Arii J, Minowa A, Kakimoto A, Koyanagi N, Kato A, Kawaguchi Y. Role of the Herpes Simplex Virus 1 Us3 Kinase Phosphorylation Site and Endocytosis Motifs in Envelope Glycoprotein B in Its Intracellular Transport and Neurovirulence. J Virol 85:5003-5015, (2011) Epub 2011 Mar 9.
  43. Toda T, Kuwahara K, Kondo N, Matsuda Z, Maeda Y, Maeda K, Sakaguchi N. Dynamic appearance of antigenic epitopes effective for viral neutralization during membrane fusion initiated by interactions between HIV-1 envelope proteins and CD4/CXCR4. Immunobiology 217(9): 864-872, 2012.
  44. Yang W, Ding X, Deng J, Lu Y, Matsuda Z, Thiel A, Chen J, Deng H, Qin Z. Interferon-gamma negatively regulates Th17-mediated immunopathology during mouse hepatitis virus infection. J Mol Med (Berl) 89:399-409, 2011.
  45. Shi G, Yagyu F, Shimizu Y, Shimizu K, Oshima M, Iwamoto A, Gao B, Liu W, Gao GF, Kitamura Y. Flow cytometric assay using two fluorescent proteins for the function of the internal ribosome entry site of hepatitis C virus. Cytometry A 79:653-60, 2011.
  46. Tsai HJ, Kobayashi S, Izawa K, Ishida T, Watanabe T, Umezawa K, Lin SF, Tojo A. Bioimaging analysis of nuclear factor-ホコB activity in Philadelphia chromosome-positive acute lymphoblastic leukemia cells reveals its synergistic upregulation by tumor necrosis factor-ホア-stimulated changes to the microenvironment. Cancer Sci 102:2014-21, 2011.
  47. Yamamoto K, Ishida T, Nakano K, Yamagishi M, Yamochi T, Tanaka Y, Furukawa Y, Nakamura Y, Watanabe T. SMYD3 interacts with HTLV-1 Tax and regulates subcellular localization of Tax. Cancer Sci 102:260-6, 2011.
  48. Kanemaru Y, Momiki Y, Matsuura S, Horikawa T, Gohda J, Inoue J, Okamoto Y, Fujita F, Otsuka M. An artificial copper complex incorporating a cell-penetrating peptide inhibits NF-kB activation. Chem Pharm Bull 59:1555-8, 2011.
  49. Shibata Y, Tanaka Y, Gohda J, Inoue J. Activation of the IkB kinase complex by HTLV-1 Tax requires cytosolic factors involved in Tax-induced polyubiquitination. J Biochem 150:679-86, 2011.

2010

  1. Song J, Feng H, Xu J, Zhao D, Shi J, Li Y, Deng G, Jiang Y, Li X, Zhu P, Guan Y, Bu Z, Kawaoka Y, and Chen H. The PA protein directly contributes to the virulence of H5N1 avian influenza viruses in domestic ducks. J Virol 85:2180-2188, (2011) Epub 2010 Dec 22.
  2. Yu M, Liu X, Sun L, Chen C, Ma G, Kitamura Y, Gao GF, and Liu W. Subcellular localization and topology of porcine reproductive and respiratory syndrome virus E protein. Virus Res 152:104-114, 2010.
  3. Song XH, Xiao H, Huang Y, Fu G, Jiang B, Kitamura Y, Liu W, Liu D, and Gao GF. Serological surveillance of influenza A virus infection in swine populations in Fujian province, China: no evidence of naturally occurring H5N1 infection in pigs. Zoonoses Public Health 57:291-298, 2010.
  4. Sun Y, Liu J, Yang M, Gao F, Zhou J, Kitamura Y, Gao B, Tien P, Shu Y, Iwamoto A, Chen Z, and Gao GF. Identification and structural definition of H5-specific CTL epitopes restricted by HLA-A*0201 derived from the H5N1 subtype of influenza A viruses. J Gen Virol 91:919-930, 2010.
  5. Kondo N, Miyauchi K, Meng F, Iwamoto A, and Matsuda Z. Conformational changes of the HIV-1 envelope protein during membrane fusion are inhibited by the replacement of its membrane-spanning domain. J Biol Chem 285:14681-14688, 2010.
  6. Nidom CA, Takano R, Yamada S, Sakai-Tagawa Y, Daulay S, Aswadi D, Suzuki T, Suzuki Y, Shinya K, Iwatsuki-Horimoto K, Muramoto Y, and Kawaoka Y. H5N1 influenza viruses from pigs in Indonesia. Emerg Inf Dis 16:1515-1523, 2010.
  7. Chen Y, Zhong G, Wang G, Deng G, Li Y, Shi J, Zhang Z, Guan Y, Jiang Y, Bu Z, Kawaoka Y, and Chen H. Dogs are highly susceptible to H5N1 avian influenza virus. Virology 405:15-19, 2010.
  8. Le QM, Ito M, Muramoto Y, Hoang PV, Vuong CD, Sakai-Tagawa Y, Kiso M, Ozawa M, Takano R, and Kawaoka Y. Pathogenicity of highly pathogenic avian H5N1 influenza A viruses isolated from humans from 2003 to 2008 in Northern Vietnam. J Gen Virol 91:2485-2490, 2010.
  9. Sakabe S, Iwatsuki-Horimoto K, Horimoto T, Nidom CA, Le MQ, Takano R, Kubota-Koketsu R, Okuno Y, Ozawa M, and Kawaoka Y. A cross-reactive neutralizing monoclonal antibody protects mice from H5N1 and pandemic (H1N1) 2009 virus infection. Antiviral Res 88:249-55, (2010) Epub 2010 Sep 16.
  10. Hatta Y, Hershberger K, Shinya K, Dubielzig RR, Hatta M, Kawaoka Y, and Suresh M. Viral replication rate regulates clinical outcome and CD8 T cell responses during highly pathogenic H5N1 influenza virus infection in mice. PLoS Pathog 6:e1001139, 2010.
  11. Imai H, Shinya K, Takano R, Kiso M, Muramoto Y, Sakabe S, Murakami S, Ito M, Yamada S, Le MQ, Nidom CA, Sakai-Tagawa Y, Takahashi K, Omori Y, NodaT, Shimojima M, Kakugawa S, Goto H, Iwatsuki-Horimoto K, Horimoto T, and Kawaoka Y. The HA and NS genes of human H5N1 influenza A virus contribute to high virulence in ferrets. PLoS Pathog 6:e1001106, 2010.
  12. Octaviani CP, Ozawa M, Yamada S, Goto H, and Kawaoka Y. High genetic compatibility between swine-origin H1N1 and highly pathogenic avian H5N1 influenza viruses. J Virol 84:10918-10922, 2010.
  13. Yamada S, Hatta M, Staker BL, Watanabe S, Imai M, Shinya K, Sakai-Tagawa Y, Ito M, Ozawa M, Watanabe T, Sakabe S, Li C, Kim JH, Myler PJ, Phan I, Raymond A, Smith E, Stacy R, Nidom CA, Lank SM, Wiseman RW, Bimber BN, O窶僂onnor DH, Neumann G, Stewart LJ, and Kawaoka Y. Biological and structural characterization of a host-adapting amino acid in influenza virus. PLoS Pathog 6:e1001034, 2010.
  14. Sakai-Tagawa Y, Ozawa M, Tamura D, Le QM, Nidom CA, Sugaya N, and Kawaoka Y. Sensitivity of influenza rapid diagnostic tests to H5N1 and 2009 pandemic H1N1 viruses. J Clin Microbiol 48:2872-2877, 2010.
  15. Kiso M, Kubo S, Ozawa M, Le QM, Nidom CA, Yamashita M, and Kawaoka Y. Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses. PLoS Pathog 6:e21000786, 2010.
  16. Shinya K, Makino A, Hatta M, Watanabe S, Kim JH, and Kawaoka Y. A mutation in H5 haemagglutinin that conferred human receptor recognition is not maintained stably during duck passage. J Gen Virol 91:1461-1463, 2010.
  17. Kiso M, Takahashi K, Sakai-Tagawa Y, Shinya K, Sakabe S, Le QM, Ozawa M, Furuta Y, and Kawaoka Y. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci USA 107:882-887, 2010.
  18. Miyauchi K, Curran AR, Long Y, Kondo N, Iwamoto A, Engelman DM, and Matsuda Z. The membrane-spanning domain of gp41 plays a critical role in intracellular trafficking of the HIV envelope protein. Retrovirology 7:95, 2010.
  19. Liu S, Kondo N, Long Y, Xiao D, Iwamoto A, and Matsuda Z. Membrane topology analysis of HIV-1 envelope glycoprotein gp41. Retrovirology 7:100, 2010.
  20. Liu J, Wu P, Gao F, Qi J, Kawana-Tachikawa A, Xie J, Vavricka CJ, Iwamoto A, Li T, Gao GF. Novel Immunodominant Peptide Presentation Strategy: a Featured HLA-A*2402-restricted cytotoxic T-lymphocyte epitope stabilized by intrachain hydrogen bonds from severe acute respiratory syndrome Coronavirus nucleocapsid protein. J Virol 84:11849-57, (2010) Epub 2010 Sep 15.
  21. Yu L, Aoki C, Shimizu Y, Shimizu K, Hou W, Yagyu F, Wen X, Oshima M, Iwamoto A, Gao B, Liu W, Gao GF, and Kitamura Y. Development of a simple system for screening anti-hepatitis C virus drugs utilizing mutants capable of vigorous replication. J Virol Methods 169:380-384, (2010) Epub 2010 Aug 14.
  22. Ashida H, Kim M, Schmidt-Supprian M, Ma A, Ogawa M, Sasakawa C. A bacterial E3 ubiquitin ligase IpaH9.8 targets NEMO/IKKホウ to dampen the host NF-ホコB-mediated inflammatory response. Nat Cell Biol 12:66-73, (2010) Epub 2009 Dec 13.
  23. Kiso M, Shinya K, Shimojima M, Takano R, Takahashi K, Katsura H, Kakugawa S, Le MT, Yamashita M, Furuta Y, Ozawa M, Kawaoka Y. Characterization of oseltamivir-resistant 2009 H1N1 pandemic influenza A viruses. PLoS Pathog 6:e1001079, 2010
  24. Grandea AG 3rd, Olsen OA, Cox TC, Renshaw M, Hammond PW, Chan-Hui PY, Mitcham JL, Cieplak W, Stewart SM, Grantham ML, Pekosz A, Kiso M, Shinya K, Hatta M, Kawaoka Y, Moyle M. Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. Proc Natl Acad Sci U S A 107:12658-12663, (2010) Epub 2010 Jul 1.
  25. Monteerarat Y, Sakabe S, Ngamurulert S, Srichatraphimuk S, Jiamtom W, Chaichuen K, Thitithanyanont A, Permpikul P, Songserm T, Puthavathana P, Nidom CA, Mai le Q, Iwatsuki-Horimoto K, Kawaoka Y, Auewarakul P. Induction of TNF-alpha in human macrophages by avian and human influenza viruses. Arch Virol 155:1273-1279, (2010) Epub 2010 Jun 9.
  26. Li C, Hatta M, Nidom CA, Muramoto Y, Watanabe S, Neumann G, and Kawaoka Y. Reassortment between avian H5N1 and human H3N2 influenza viruses creates hybrid viruses with substantial virulence. Proc Natl Acad Sci USA 107:4687-4692, 2010.
  27. Sun Y, Liu J, Yang M, Gao F, Zhou J, Kitamura Y, Gao B, Tien P, Shu Y, Iwamoto A, Chen Z, Gao GF. Identification and structural definition of H5-specific CTL epitopes restricted by HLA-A*0201 derived from the H5N1 subtype of influenza A viruses. J Gen Virol 91:919-930, (2010) Epub 2009 Dec 2.
  28. Koga M, Kawana-Tachikawa A, Heckerman D, Odawara T, Nakamura H, Koibuchi T, Fujii T, Miura T, Iwamoto A. Changes in impact of HLA class I allele expression on HIV-1 plasma virus loads at a population level over time. Microbiol Immunol 54:196-205, Apr (2010).
  29. Zhu D, Kawana-Tachikawa A, Iwamoto A, and Kitamura Y. Influence of polymorphism in dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin-related (DC-SIGNR) gene on HIV-1 trans-infection. BBRC 393:598-602, 2010.
  30. Miyake A, Ishida T, Yamagishi M, Hara T, Umezawa K, Watanabe T, Horie R. Inhibition of active HIV-1 replication by NF-kappaB inhibitor DHMEQ. Microbes Infect 12:400-408, (2010) Epub 2010 Feb 19.
  31. Ashida H, Ogawa M, Kim M, Suzuki S, Sanada T, Punginelli C, Mimuro H, Sasakawa C. Shigella deploy multiple countermeasures against host innate immune responses. Curr Opin Microbiol 14:16-23, (2011) Epub 2010 Oct 8.
  32. Morikawa H, Kim M, Mimuro H, Punginelli C, Koyama T, Nagai S, Miyawaki A, Iwai K, Sasakawa C. The bacterial effector Cif interferes with SCF ubiquitin ligase function by inhibiting deneddylation of Cullin1. Biochem Biophys Res Commun 401:268-274, (2010). Epub 2010 Sep 17.
  33. Sasakawa C. A new paradigm of bacteria-gut interplay brought through the study of Shigella. Proc Jpn Acad Ser B Phys Biol Sci 86:229-243, 2010.
  34. Arii J, Goto H, Suenaga T, Oyama M, Kozuka-Hata H, Imai T, Minowa A, Akashi H, Arase H, Kawaoka Y, Kawaguchi Y. Non-muscle myosin IIA is a functional entry receptor for herpes simplex virus 1. Nature 467:859-862, 2010.
  35. Arii J, Wang J, Morimoto T, Suenaga T, Akashi H, Arase H, Kawaguchi Y. A Single Amino Acid Substitution in Herpes simplex virus 1 Envelope Glycoprotein B at a Site Required for Binding to the Paired Immunoglobulin-like Type 2 Receptor a (PILRa) Abrogates PILRa-dependent Viral Entry and Reduces Pathogenesis. J Virol 84 :10773-10783, (2010) Epub 2010 Aug 4.
  36. Sagou K, Uema M, Kawaguchi Y. Nucleolin is required for efficient nuclear egress of herpes simplex virus 1 nucleocapsids. J Virol 84:2110-2121, (2010) Epub 2009 Dec 2.
  37. Imai T, Sagou K, Arii J, Kawaguchi Y. Effects of Phosphorylation of Herpes Simplex Virus 1 Envelope Glycoprotein B by Us3 Kinase In Vivo and In Vitro. J Virol 84:153-162, 2010.